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Microbial pathogens range in size, shape, as well as biochemical and molecular 
properties. This has led to the evolution of a variety of pathogen recognition receptors 
(PRRs) in mammalian immune cells that are responsible for sensing pathogen-associated 
molecular patterns (PAMPs) and initiating specific types of immune responses. However, 
the breadth of the PRR responses, especially how dendritic cells sense pathogen physical 
properties in conjunction with specific molecular patterns and translate that into unique 
immune responses, remains unknown. Here, we have developed pathogen-like particles 
(PLPs) that mimic physical properties of large viruses or bacteria to demonstrate that 
CpG-mediated dendritic cell signaling can be precisely modulated by varying PLP 
parameters, specifically size and adjuvant density. We demonstrate controlled tunability 
of DC programming, allowing directed maturation of distinct T cell phenotypes, antibody 
class switching and in vivo immune-polarization. Furthermore, we show, for the first 
time, that the surface-density of CpG on PLPs can finely control DC signaling by 
regulating the kinetics of NFκB transcription and STAT3 phosphorylation. These 
findings suggest that DCs sense physical aspects of pathogen-like materials, broadening 
the tools that can be used to modulate immunity, better understand innate immune 





CHAPTER 1  OVERVIEW, HYPOTHESIS AND SPECIFIC AIMS  
1.1 OVERVIEW 
The implementation of vaccines has been one of the most successful global health 
initiatives to date, but there are still a significant number of disease states (i.e. infectious, 
cancerous, autoimmune) that are treatable via an immunotherapy. Therefore, vaccine 
design must become more advanced in order to tackle these evasive diseases. Vaccines 
that will prove effective must target immune cells of interest so not to induce an 
undesired systemic response, provide potent and persistent modulatory signals and direct 
immune cell programming to the most effective mode of therapeutic action. Particulate 
vaccines offer a tunable platform that can be targeted (chemically or otherwise), can carry 
multiple antigens and adjuvants to ensure potent (sometimes synergistic) signaling and 
there is building evidence that they can be used to specifically direct immune cell 
activity. This evidence motivates the investigation of more efficacious vaccine designs 
that are specific to each disease, as they will each require a unique therapeutic approach. 
Furthermore, dendritic cells have been identified as the conductors of the adaptive 
immune response, as they give the primary signals to T cells, which drive the attack on 
infection. Therefore, it is essential that we gain understanding of how these cells function 
and how that function can be successfully modulated.       
Recent literature has established that there are multiple subsets of DCs in peripheral 
tissues that have the ability to direct the body’s immune response1. Biomaterials-based 
delivery systems have been shown to increase vaccine efficacy and targeting molecules 
have been added to these systems to preferentially direct vaccines to DCs2. However, it 
has not yet been explored whether physical parameters, such as size, can be used to direct 
delivery to specific DC subsets. In this work, we have demonstrated that relevant tissue-
resident DC subsets can be targeted by particle size, resulting in a distinct immunological 
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response. Furthermore, we describe a mechanism by which particles direct functional 
programming of DCs. 
1.2 HYPOTHESIS 
Our primary hypothesis was that particle parameters, specifically size and ligand 
density significantly affect the efficiency of our particles vaccines by modulating DC 
programming. The overall objective was to develop pathogen-like particle (PLP) vaccine 
delivery systems that will induce a more robust, long-lasting immune response.  
1.3 SPECIFIC AIMS 
1.3.1 Aim 1: Determine how DCs of two peripheral subsets interact with PLPs in 
vitro. 
In this aim, (a) PLGA nanoparticles (NPs) were fabricated using a method similar to 
microparticles (MPs) previously used in the lab, including cationic modification using 
branched polyethylenimine. The NPs were characterized to determine size, zeta potential 
and loading potential of various vaccine components. (b) Additionally, primary murine 
bone marrow derived dendritic cells (BMDCs) or spleen-derived DCs were grown in 
varying culture conditions that result in phenotypes relevant for vaccination. Delivery 
efficacy of these particles was tested in vitro using DCs studied previously alongside MP 
equivalents. Maturation markers, secreted cytokines and antigen presentation to CD4+ 
and CD8+ T cells were studied.  
1.3.2 Aim 2: Investigate the efficacy of PLP formulations screened in Aim 1 in 
vivo. 
This aim was split into three goals. We first investigated how PLP vaccination affected 
migration of skin-resident DC subsets and which subsets were responsible for carrying 
PLPs to draining lymph nodes. We then characterized the resultant adaptive immune 
 3 
response to determine whether PLP-size dependent immunomodulation was evident. 
Finally, we tested whether the PLP-driven immune responses were robust enough to 
protect mice against a challenge with a lethal dose of melanoma.   
1.3.3 Aim 3: Evaluate mechanism that dictates formulation size-dependent DC 
programming.  
In this aim, we deconstructed the primary pro-inflammatory signaling axis to determine 
where the divergence in signaling between micro- and nano-PLPs occurs. We 
investigated the well-characterized TLR9-NFκB signaling pathway. Specifically, we 




This work focuses on characterizes the interaction of pathogen-like particles (PLPs) with 
varying subsets of skin-resident migratory dendritic cells. Specifically, we investigated 
whether particle size or adjuvant density play a role in influencing dendritic cell 
programming, which thereby attenuates downstream immune events. CHAPTER 2 
provides a short overview of the immune-biology, focusing on dendritic cells (DC) of the 
innate immune response and their subsequent signals to cells of the adaptive immune 
response. We further elaborate on DC subset biology and then discuss the state of the 
field of molecular adjuvant research and how particle carriers can be considered 
adjuvants. PLP characterization and in vitro dendritic cell culture development are 
discussed in CHAPTER 3 , along with the demonstration that DC subsets exhibit 
preferences for different sized carriers and that size plays a critical role in DC 
programming. 3.4validates this dichotomy in vivo and further demonstrates the 
immunomodulatory potential of carrier size through their ability to tune T cell mediated 
systemic immunity. In CHAPTER 5 we have proposed a mechanism by which particle 
size mediates the observed shift in DC programming. We have demonstrated that nano-
PLPs, despite being taken up at a similar rate and magnitude as micro-PLPs, promote 
delayed signaling through TLR9, leading to inhibition of downstream signaling 
processes. Furthermore, we observed rapid activation of an inhibitory pathway in cells 
treated with nano-PLPs. Finally, CHAPTER 6 discusses implications of these studies 




CHAPTER 2  BACKGROUND AND SIGNIFICANCE1,2 
Immunotherapy is the use of drugs and/or biological agents to initiate, modulate and 
control an immune response. There is a wide range of immunotherapeutic strategies that 
are currently being investigated for both prophylactic and therapeutic purposes. Some of 
these have been previously reviewed in detail3. Prophylactic immunotherapy (i.e. 
vaccination) refers to the use of specific antigens along with immunomodulators or 
immunostimulators (often referred to as adjuvants) to generate protective immunity 
against future infections or antigenic challenge while therapeutic immunotherapies are 
applied after the onset of a disease. This chapter focuses on polymer-based nano and 
microparticle carriers for vaccine-related applications, although most of the concepts 
presented here are broadly applicable for immunotherapies in general. 
  
                                                
 
 
1 Leleux, J. and Roy, K. (2013), Micro and Nanoparticle-Based Delivery Systems for Vaccine 
Immunotherapy: An Immunological and Materials Perspective. Advanced Healthcare Materials, 2: 72–94. 
doi: 10.1002/adhm.201200268 – used with permission from publisher (License #: 369151318056) 
2 Leleux, J., Atalis, A., Roy, K. (2015), Engineering Immunity: Modulating Dendritic Cell Subets and 
Lymph Node Response to Direct Immune-polarizatoin and Vaccine efficacy. Journal of Controlled 
Release, In Review. 
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2.1 IMMUNITY: A PRIMER 
Before Edward Jenner’s discovery of the cross-reactive cowpox vaccine two centuries 
ago, which eventually eradicated smallpox in humans, the primary disease prevention 
strategy was to intentionally induce a mild infection using pathogenic serum or lysate. 
While these techniques often provided protection, there were also many cases of severe, 
even fatal reactions4. As safety concerns have risen and biological technology 
modernized, scientists have begun to develop vaccines with four crucial criteria in mind: 
they must be safe, effective, scalable and cheap while at the same time provide a robust, 
long-term immune response.   
2.1.1 Inducing a robust memory response: innate and adaptive immunity 
The immune response is separated into innate immunity and adaptive immunity. The 
main differentiating factors between the two are the response time and the level of 
specificity. The innate response is initiated almost immediately and involves the 
migration of phagocytic cells, mainly macrophages and dendritic cells (DCs) to the site of 
infection5,6. While all of these cell types have the ability to present antigen, DCs are 
considered to be the primary antigen presenting cells (APCs). Immature DCs migrate out 
of the bone marrow and reside in the bloodstream and peripheral tissue where they 
encounter pathogens or antigen. Once this interaction occurs and the DC ingests a 
microbe or other antigen, it undergoes directed activation and maturation. As the name 
APC implies, the cells digest (process) pathogens and present highly specific peptides on 
their surface in combination with a major histocompatibility complex (MHC I or MHC II 
in mice, HLA or Human Leukocyte Antigens in humans) that provide signals through the 
T cell receptor complex to induce T cell maturation, specificity and subsequent clonal 
expansion (Figure 1)7. Additionally, costimulatory molecules, such as CD40, CD83, and 
CD86 move to the surface of the APC where they provide critical stimulatory signals in T 
lymphocyte activation8,9. Finally, activated APCs begin to secrete immunomodualtory 
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cytokines, such as IL12p70, IL10 and IL6. The specific combination of MHC complexes 
carrying antigen specific peptides, costimulatory molecules expressed on the surface of a 
DC and immunomodulatory cytokines directs T lymphocyte activation and 
functionalization10. Expression of an MHC class I molecule on the surface of a DC and 
secretion of IL12p70 will more often result in the differentiation of an immature T 
lymphocyte to a CD8 expressing cytotoxic T lymphocyte (CTL). MHC class II molecules 
will induce the maturation of CD4-expressing-helper T cells (Th cells)11. CTLs go on to 
eliminate pathogen-infected cells and are being studied as a potential stategy for cancer 
eradication12. Th cells’ have a wide variety of functions that are highly dictated by DC 
signals (i.e. cytokines) including facilitating B cell activation, which induces the humoral 
immune response, and promoting maturation of other T cells. In some cases, CD4 is also 
expressed on the surface of CTLs13.  
After helper T cell differentiation and antigen specification, these cells are able to 
provide secondary costimulatory signals to B lymphocytes that have been activated by an 
antigen. This secondary signal is essential for B lymphocyte maturation into a plasma 
cell. Mature plasma cells produce antigen-specific serum and mucosal antibodies14. 
Antibodies participate in host defense by neutralizing toxins and coating pathogens to aid 
in phagocyte identification.   
Humoral immunity has been targeted for years in order to develop effective 
vaccines. Significantly increased titers and long residence time of antigen specific 
antibodies are the hallmarks of an effective inoculation regimen15,16. However, with 
increasing safety restrictions and the need for a robust cellular response to persistent or 
immune-evading pathogens, the addition of specific adjuvants to vaccines can enhance 
cell-mediated immunity and provide immunostimulatory enhancement to ensure 

















2.1.1.1 DC Subsets 
It is now recognized that based on primary location, DCs can be sub-categorized into 
many functionally distinct groups, extending the influence that DCs have on immunity. In 
addition to DC subsets in the periphery, there are also lymphoid-resident DC subsets that 
have significant impact on T cell maturation 17–19. In this section, we will discuss some of 
the key subsets and their functional differences. Table 1 provides a summary of these DC 
subsets, along with surface markers used to distinguish and isolate them, the related 
maturation markers and primary cytokine types that the cells secrete upon activation and 
maturation. While this table includes human subsets, we will focus on murine DCs in this 
section. Additionally, Figure 2 delineates the skin, lymphatics, and lymph node 
biointerface, designating the relevant anatomy, various DC subsets present, and 
highlighting that peripheral DCs must migrate to the local immune hubs (i.e. draining 





Table 1: DC Subsets: Location and Function 
DC Subset Primary Location Species Phenotype Function† Source 
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†DC subsets not limited to these functions; those listed are discussed in this review 







Figure 2: Schematic of skin and lymph node resident DC subsets.   
 
2.1.1.1.1 Secondary Lymphoid Organ Resident Dendritic Cells 
Secondary lymphoid organ resident dendritic cells were the first to be classified in the 
mouse system by Steinman and Cohn over 40 years ago 42. Since their initial discovery 
and characterization, our understanding of their complexity has greatly increased, leading 
to multiple sub-classifications with very different functions. To date, these DCs are 
placed into two subsets based on their expression of CD8α and CD11b and their 





CD8α+DCs, also characterized by their expression of C-type lectin receptor DEC-205 
(CD205) but not integrin CD11b, have been the most extensively studied and shown to 
efficiently cross-present antigen, induce CD8+ T cell activity and cytotoxic behavior 
17,18,20. A functionally homologous cell type was only recently discovered in the human 
system and is characterized by its expression of BDCA-3 (discussed later in this 
section)43,44. Is has also been shown that CD8α+ DCs have the ability to receive antigen 
from migratory DCs that arrive from the peripheral tissues for presentation to CD8+ T 
cells, effectively increasing the range of T cell activation associated with relatively few 
migratory cells in the LNs 45. This antigen exchange may not be isolated to proteins, but 
may also include glycolipid antigens essential for natural killer-T cell activation 46. 
Additionally, CD8α+ DCs play a role in maintaining self-tolerance by promoting self-
reactive T cell proliferation and subsequent elimination, as well as maturation of Foxp3+ 
regulatory T (Treg) cells 19,47.  
 
CD8α- (CD11b+) DC  
CD11b+ lymphoid DCs do not express CD8α nor high levels of DEC-205, but can 
express CD4 and interact primarily with CD4+ T cells 18,22. These cells preferentially 
activate a type II helper response from CD4+ T cells, likely due to their proficiency in 
MHC II antigen presentation 48–50. These cells also exist in a double negative (CD8- 
CD4-) state and maintain their ability to promote type II polarization of the helper T cell 
(Th) response. However, CD4+ DCs have also been shown to secrete type I associated 
cytokines, such as IL-12, when activated by certain toll-like receptor (TLR) agonists, 
linking these cells to antiviral immunity with the appropriate signals 51. Lastly, these cells 
are the predominant scavengers of antigen that circulate through the lymphoid organs, 




The final subset of lymphoid-resident dendritic cells is plasmacytoid DC (pDC), which 
has been identified in secondary lymphoid tissues as well as blood and certain peripheral 
tissues (mostly during inflammatory episodes) 52,53. pDCs have been shown to differ from 
conventional DCs in morphology, migration patterns, and primary function 54,55. Their 
hallmark is the ability to secrete large amounts of type I interferon after exposure to viral 
pathogenic patterns, particularly agonists for TLRs 7 and 9 23,24,56. These receptors 
typically recognize pathogenic RNA and DNA, respectively, and have mechanisms by 
which they differentiate these patterns from autogenic nucleic acid debris 57. However, 
there is recent evidence that certain disease states can promote recognition of self-DNA, 
leading to overproduction of type I interferon and autoimmunity 58–60. pDCs have also 
been implicated in Treg priming, plasma cell differentiation and tolerance against 
allergies 61–65. 
2.1.1.1.2 Skin-resident Dendritic Cell Subsets 
Though peripheral dendritic cells reside in many organs such as the gut, intestine, and 
lungs, skin and muscle are the most common sites of vaccination. Because of recently 
developed devices such as microneedles and needle free injectors, skin-based vaccination 
is gaining further importance. Furthermore, significant knowledge exists on skin-resident 
DCs, their various subsets, and related lymphatic transport; which will be the primary 
focus of this section. 
 
Langerhans cells 
Langerhans cells (LCs) are epidermal DCs characterized by their Birbeck granules, 
formed by the C-type lectin receptor, Langerin 27,66. They specialize in surveying the 
epidermis for antigen, extending their dendrites between apical cells 67. In mice, LCs 
(mLCs) can promote and regulate multiple T cell-mediated responses 40,68,69. They 
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primarily present antigen via MHC II to induce proliferation of Th17 cells, known for 
mediating immunity against bacteria and fungi, and Th2 cells, required for humoral 
immunity against large extracellular pathogens 28,29. However, the ability of mLCs to 
induce type I helper immunity is controversial. In mice infected with Candida albicans, 
mLCs were unable to induce Th1 responses or cross-present antigens to CD8+ T cells 29. 
However, Nizza et al. observed that murine CD11b+ Langerin+ migratory DCs (mainly 
mLCs) were able to cross-prime naïve CD8+ T cells and imprint them with skin-homing 
specificity 30. mLCs can also induce proliferation of Treg cells and restrain self-reactive T 
cells, suppressing inflammation and autoimmunity 28.  
 
Dermal Dendritic Cells 
Within the dermis are conventional DCs (cDCs), distinguishable from their lymphoid-
resident counterparts by their intermediate to high levels of CD11c and high levels of 
MHC II 70,71. In both homeostatic and inflammatory conditions, they travel from the skin 
to lymph node guided by the chemokine receptor, CCR7, which will be discussed in 
greater detail later. At steady state, dermal DCs present self-antigens, aiding in 
maintenance of peripheral tolerance. However, when they encounter a pathogen, dermal 
DCs mature similarly to LCs and upregulate costimulatory molecules on their surface in 
order to activate antigen-specific CD4+ and CD8+ T cells. The two major murine dermal 
DC subsets are CD103+ and CD11b+ DCs 67,72. 
In the dermis, CD103+ DCs express Langerin but not CD11b (although some are 
CD11blo) 31,67. These dermal DCs are most known for their superior ability to cross-prime 
CD8+ T cells 32.. In addition to cross-presentation, CD103+ DCs also drive Th1 and 
Th17 cell differentiation 29,73. 
CD11b+ DCs express DEC-205, but not Langerin 31,67,71. They are the most 
abundant type of DC in a healthy dermis and share phenotypical characteristics with 
monocyte-derived DCs that infiltrate tissue during inflammation 34,74. They can also be 
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broken down into further subcategories with varying functions but their predominant role 
is thought to be MHC II presentation and induction of Treg and Th cells 75,76. For 
example, Plantinga et al. observed that migratory CD11b+ cDCs but not CD103+ DCs 
initiated Th2 cell-mediated immunity against house dust mite allergen in the lymph 
node34. Though they do not directly activate Treg cells, they express the enzyme 
aldehyde dehydrogenase that metabolizes vitamin A into retinoic acid, which has been 
implicated in Foxp3+ Treg cell generation in vitro 35,77,78.  
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2.1.1.1.3 DC Migration 
Migratory dendritic cells travel to the lymph node through afferent lymphatic vessels in 
homeostatic and inflammatory conditions. Tissue-resident dendritic cells are constantly 
presenting antigens; in the steady state, they present self-antigens via MHC II, resulting 
in tolerogenic activity. Immature migratory dendritic cells do not express high levels of 
co-stimulatory molecules such as CD40, CD80, or CD86, which bind to receptors on T 
cells during activation 79,80. In the presence of MHC II without engagement of co-
stimulatory molecules, T cells either die or become anergic 81. Immature, migratory DCs 
can also convert naïve CD4+ T cells into Tregs 82. 
It is well known that DCs activated by microbial antigens and inflammatory 
stimuli upregulate chemokine receptor CCR7, which binds to ligands CCL21/SLC and 
CCL19/ELC for recruitment to the lymphatic vessels 83–85. CCL21 is released by 
lymphatic endothelial cells (LECs) and is highly concentrated around the vessel, since it 
binds to sulfated proteoglycans (i.e. heparin) 86,87. On the other hand, CCL19 is more 
soluble and acts in both autocrine and paracrine fashions, as it is released by both 
dendritic cells and LECs 87. While this recruiting mechanism may play a role in steady 
state maturation and migration, there is still much to learn. Baratin et al. speculates NF-
κB signaling is required for maturation and migration and demonstrates IKKβ deletion is 




2.1.1.2 Adjuvants: Enhancing immunity through pathogenic recognition 
While the innate response is not considered specific and will not retain any memory of a 
previous infection, there are mechanisms at the DC level that can provide the initial 
direction of the immune response. Adjuvants can be categorized into two groups: 
immunostimulatory molecules and antigen delivery vehicles89. The immunostimulatory 
molecules that are responsible for guiding specific cytokine production by DCs as well as 
DC activation are called pattern recognition receptors (PRRs), which are individually 
stimulated by a class of molecules called pathogen associated molecular patterns 
(PAMPs). PAMPs are being extensively investigated as adjuvants to activate specific 
PRRs and thereby control the DC behavior towards a specific type of immune response 
and thus increase vaccine efficacy6. The sections below provide an overview of DC-
related PRRs and their associated PAMPs. 
2.1.1.2.1 Membrane-spanning PRRs 
Toll-like receptors (TLRs) are transmembrane proteins located on the cell and endosomal 
membranes (Figure 3). Their position correlates to the type of adaptive immune response 
that they induce (Table 2)90–93. Therefore, TLR ligands (PAMPs) can be selected to 
specifically engineer adjuvants that elicit predictable reactions. The recognition of 
lipopolysaccharide by TLR4 was the first of the TLR-ligand relationships to be 
elucidated and has since driven further investigation of how TLRs affect the end point of 
an immune response6. Other TLRs that recognize bacteria-derived ligands are TLR1, 2, 5 
and 6, which all reside on the cell membrane94,95. Their location allows them to interact 
with bacteria cell wall constituents, such as lipopolysaccharide, flagellin or lipoproteins. 
TLRs 3, 7/8, and 9 are recruited to the endosomal membrane upon the uptake of viral 
components. These TLRs recognize double-stranded RNA (e.g. poly(I:C)), single-
stranded RNA and unmethylated CpG motifs in DNA, all of which are not native to 
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mammalian cells92. With the exception of TLR3, all of the TLRs are associated with a 
MyD88 dependent signaling pathway, which is responsible for the downstream activation 
of many transcription factors, most significantly NF-κB96,97. NF-κB positively regulates 
the production of cytokines crucial to the adaptive immune response98,99. These cytokines 
play an essential role in determining the direction of the innate response and 
subsequently, the cellular response100. In the case of MyD88 inhibition or damage, TLR3 
and 4 can also trigger a MyD88 independent pathway via the adaptor protein TRIF that 
results in the production of the antiviral cytokine IFN-β101. Utilization of specific 
activation of these receptor-ligand interactions has become of particular interest for 










Figure 3: Toll-like receptors on APC cell and endosomal membranes recognie specific 
patterns associated with pathogenic molecules.  
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Table 2: Toll-like receptors and their ligands 
TLR Receptor Location PAMP recognized Cell Response 
TLR 1 cell membrane bacterial triacyl lipopeptides Induce production of inflammatory cytokines 
TLR 2 cell membrane 
- bacterial lipoproteins/lipopeptides 
and lipopolysaccharides of non-
enterobacteria 
Induce production of 
inflammatory cytokines 
  - fungal β-glucan  
TLR 3 endosome viral double stranded RNA/ polyinosinic: polycytidylic acid 
Synthesis of type 1 
interferons 
TLR 4 cell membrane - lipopolysaccharaide from Gram-negative bacteria 
Synthesis of type 1 
interferons 
  - heat shock proteins  
  
- domain A of fibronectins, hyaluorinic 
acid, heparan sulfate and fibrinogen  
TLR 5 cell membrane bacterial flagellin 
Found in intestinal 
endothelium and lung 
epithelium which 
implicates its 
importance in mucosal 
immunity 
TLR 6 cell membrane bacterial diacyl lipopeptides Induce production of inflammatory cytokines 
TLR 7 endosome Imidazoquinoline/ Single stranded RNA Anti-viral response 
TLR 8 endosome Imidazoquinoline (in humans)/ Single stranded RNA Anti-viral response 
TLR 9 endosome Unmethylated CpG motifs Dependent on type of CpG 
   
Type A/D induces 
IFN-α 
   
Type B/K induces IL-12 
and TNF-α production 
TLR 10 unknown unknown unknown 
TLR 11 cell membrane Uropathogenic bacterial components Prevention of urinary tract infection 
TLR 12/13 only in mice -- unknown unknown unknown 
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2.1.1.2.2 Cytoplasmic PRRs 
Pathogenic material can also be detected intracellularly by a series of cytoplasmic 
receptors including RIG-1-like receptors (RLRs), nucleotide-binding domain-like 
receptors (NLRs) and C-type lectin receptors (CLRs)103,104. RLRs recognize viral 
replication byproducts such as dsRNA in the cytoplasm and subsequently activate NF- 
κB and type 1 interferon production103. While about 30 NLRs have been identified, only 
the functions of nucleotide-binding domain-1 (NOD-1) and NOD-2 have been elucidated. 
Peptidoglycan containing components of bacteria are recognized by NOD-1 and NOD-2 
which also results in induction of an inflammatory response lead by NF- κB activation105. 
CLRs also identify cell wall components but specifically of mycobacteria. CLR 
activation is implicated in promoting the generation of type 1 helper T cells106. In 
addition to the use of single PAMPs for APC activation and innate immunity direction, 
the synergistic effect of combining multiple PAMPs as adjuvants is being thoroughly 
investigated107,108. 
2.1.1.2.3 Delivery vehicles as adjuvants 
Delivery vehicle adjuvants are most often particulate in nature and include polymer 
particles, emulsions, liposomes, virosomes and others109. Their main functions are to 
stabilize the antigen by protecting it from the surrounding biological conditions, to slow 
down the clearance of antigens or diffusion of adjuvant from the site of injection and to 
enhance delivery to antigen presenting cells (APCs)110.  
Antigen delivery systems, while not always being inherently immunostimulatory 
do promote the necessary interactions for antigens to be efficiently presented to DCs for 
humoral and cellular memory. There are three important steps that are essential for a 
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vaccine to be efficacious: targeting, activation and transfection/antigen presentation.  
While this process has recently been reviewed it is worth being discussed briefly here111. 
Before an antigen is taken up by an APC, it is vulnerable to its surrounding environment, 
which consists of numerous enzymes that can denature the antigen such that it no longer 
has immunomodulatory abilities. The first benefit of particulate antigen delivery is the 
protection it provides the antigen from premature degradation in biological 
environments112. Once the antigen is stable in the body, it is critical that it is found and 
taken up by an APC, ideally a DC.  Another benefit of particle delivery is tighter control 
on the active and passive targeting to APCs to increase uptake of the antigen113. 
Regardless of route of delivery, soluble antigens and adjuvants rarely reach the 
appropriate antigen presenting cells; therefore the resulting immune response is not 
potent enough for long term protection. This is partially because of the rapid rate at which 
hydrophilic or small molecule adjuvants diffuse into systemic circulation114,115. Particles 
mimic the size and structure of a pathogen, so APCs are more likely to take up particles 
than soluble antigen. Especially when combined with chemokines and/or APC targeting 
molecules, particles can simulate a depot for the antigen, increasing the efficiency of 
delivery of the antigen to APCs. Additionally, controlled release of antigen and other 
molecules can lead to prolonged presentation to APCs. Particles can also aid in 
facilitating endosomal release of the antigen post-uptake, which is necessary for antigen 
cross-presentation within the APC116,117. Cross presentation is an important mechanism 
for the surface expression of MHC I molecules, which is critical for the production of 
CD8+ cytotoxic T cells (CTLs). Generally antigens that are phagocytosed will be 
presented by MHC class II molecules, which generate CD 4+ T cells causing antibody 
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production and other humoral responses. However, in the case of persistent viruses and 
cancer, this response is not sufficient; a cellular response is also necessary. Therefore, 
cross-presentation of the antigen to promote expression of a MHC I-antigen complex is 
essential118. In addition to cross presentation, endosomal release allows for DNA 
vaccines to migrate to the cell nucleus where they can transfect the cell119. 
Lastly, particulate delivery of antigens allows the co-delivery of multiple 
molecules, i.e., antigen and adjuvants to the same cell and potentially at higher doses than 
would be possible in soluble conditions. This increases the probability that the intended 
response will be observed due to discretized heightened response on an individual cell 
basis. These enhancements would affect both the antibody response produced by B cells 




2.2  PARTICLES FOR DELIVERY OF ANTIGEN AND ADJUVANTS: 
PATHOGEN-LIKE PARTICLES AS VACCINES 
Particle-based delivery systems have gained attention due to their potential benefits as 
drug and vaccine carriers. These carriers should incorporate several design constraints: 
they must be biocompatible, able to deliver a variety of drugs or vaccines that can be 
released in a targeted and controlled fashion, must be stable throughout processing and 
delivery in vivo and should be biodegradable or easy to clear120. The following sections 
will elaborate on various polymer-based particulate delivery systems and will address 
how they fulfill the above design criteria.  
2.2.1 Comparison of particle parameters 
Many particulate systems have been effective in eliciting an immune response; however, 
it is important to understand how the many differences in physical properties can render a 
particular technique useful for specific applications. Specifically, particle size has been 
heavily studied in the context of immune cell uptake and some aspects of 
immunomodulation, but there is still no consensus about how size can be used to 
specifically direct immunity. Additionally, ligand density is inherently coupled with size 
and has been relatively unstudied compared to many other parameters. This section will 
discuss the major claims provided by size and ligand density studies to date.  
2.2.1.1 Does Size Matter? 
Particle size is a critical factor that can drastically affect interaction of particles with cells 
as well as their biodistribution. In drug delivery, particles in the nanometer range are 
considered attractive in vivo carriers because they can easily permeate tissue barriers (e.g. 
vasculatures) and better migrate into target tissues, especially in diseased tissues like 
tumors121. However, size-effects for particles designed to target immune cells and their 
ultimate influence on the immune response, has not been definitively established. It is 
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postulated that particles of several microns in size would be phagocytosed readily and 
thus provide improved delivery of antigens and adjuvants to APCs122. However, 
pathogenic material is often smaller than a micron; viruses can even be tens of 
nanometers in diameter. Additionally, particles larger than 100 nm have difficulty 
moving into lymphatic vessels and traveling to the lymph nodes, where they can increase 
the probability of immune cell interaction117. Particle size also influences a cell’s 
mechanism of uptake, some of which are more efficient than others. How a cell takes up 
a vaccine could eventually determine how it processes the antigen123.  
Although several groups have investigated how size correlates to immunotherapeutic 
benefits, the inherent complexity of the immune response makes pinpointing an optimal 
solution difficult. There is some evidence that smaller particles can induce a type 1, 
antiviral response while immunization with larger particles tends to induce a more 
significant humoral reponse124,125. Additionally, particle size effects could vary with route 
of administration126. For example, while particles 100 nm in diameter are taken up more 
efficiently in the Peyer’s patch after oral immunization, particles this size are not suitable 
for an intranasal or inhalable vaccination122,127. Lastly, as discussed earlier, particle size 
can dictate whether particles can be transported via interstitial flow to the lymph nodes. 
Reddy et al. demonstrated that the cutoff for efficient movement of particles through the 
lymphatic capillaries is about 45 nm128. Table 3 provides more examples of studies 
investigating how particle size has an impact on the resultant immunity. 
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Table 3: Effect of particle-size on immune response 
Type of Particle Particle Size Range Application Results 
PLGA127  100nm, 500nm,  1µm, 10 µm 
In situ GI tract tissue uptake 
in rats 
60% increase 
 100nm uptake in Peyer's 
patch. Larger particles in 
epithelium. 
PLGA129  200 nm  and 2 µm 
Targeted and nontargeted 
particles to deliver antigen to 
human DCs in vitro 
MPs more nonspecific 
uptake. Targeting enhanced 
NP uptake.. 
PLGA126 200 nm, 500 nm,  1 µm 
Particle size dependent serum 
antibody response following 
immunization IN, OR and 
SC.. 
Administration of largest 
particles (1 µm) elicited 




10-70 µm, 2-8 µm,  
less than 2 µm 
Particles loaded with tetanus 
toxoid for long term anti-TT 
antibody titer  
2-8 µm MPs elicited the 




positive and neutral)131  
50, 100,  
200, 500 nm 
Permeation of nanoparticles 
for transdermal vaccine 
delivery using pig skin 
Negatively charged 50nm 
and 500nm particles 




100 nm, 500 nm,  
1 µm, 4.5 µm 
Optimal DC uptake to 
enhance antigen delivery 
<500nm NPs taken up best 
by DCs  
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Table 3: Effect of particle-size on immune response 
Type of Particle Particle Size Range Application Results 
Fluorescent 
Polystyrene133 
930 nm, 1.87 µm, 
 2.3 µm, 2.98 µm, 
4.3 µm, 5.71 µm, 9 
µm 
Investigate the dependence of 
size on phagocytosis 
2 µm-3 µm MPs preferentially 
phagocytosed by alveolar 
macrophages. 
Polystyrene 124 
20 nm, 40 nm,  
49 nm, 67 nm,  
93 nm, 101 nm,  
123 nm 
NP uptake by DCs and 
induction of type 1 or type 2 
responses 
40-49 nm NPs had highest IFN-γ. 






Ultra-small versus small NPs 
transport to lymph modes via 
interstitial flow 
25 nm NPs 10x more efficient 
drainage to LNs than 100nm NPs  
Various 120 500 nm - 5 µm 
Intranasal or inhaled delivery of 
vaccines for mucosal 
immunization 
> 5 µm MPs will not reach the 
deep lung. <500 nm will be 
immediately exhaled. 
Various122 1 - 5 µm Maximum interaction with phagocytic cells 
Particles this size will be 
efficiently taken up. 






2.2.1.2 Does Ligand Density Matter? 
Particle surface area to volume ratio varies as a function of size, with smaller particles 
having a larger ratio. This means that when testing particulate vaccines that it is 
impossible to keep antigen/adjuvant dose, particle mass and ligand density the same for 
all formulations. Therefore, it is essential to quantify which of these variables plays the 
greatest role in immune-modulation. It is now well established that antigen and adjuvant 
dose play a large role in generating robust immunity130,135–138. While some have argued 
that APCs response directly to material properties85,139, it is thought that (and we have 
observed) at the small dose associated with vaccination that APC programming is 
dominated by other molecular signals. Interestingly, there has been very little attention 
given to the importance of ligand density. One study examined whether density of 
targeting ligands (anti-DEC-205) on PLGA carriers would induce variable responses 
from DCs. They found that production of the regulatory cytokine IL10 was correlated 
with increased anti-DEC-205 density, which they attributed to cross-linking of DEC-205 
receptors at higher densities. This cross-linking event caused DCs to express scavenger 
receptor CD36, which they found was directly linked to the IL10 response140. Clearly this 
variable needs to be further studied, especially in the context of how antigen and adjuvant 
density changes immune cell programming.    
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2.3 FUTURE DIRECTIONS 
Over the past several decades, particulate vaccine carriers have been extensively reported 
on. However, broad success in human immunotherapy has been largely elusive. The 
benefits of particle based systems including protection of antigens and adjuvants, ability 
to directly target specific antigen-presenting cells, extended release of vaccine 
components (depot effect) and ability to deliver vaccine components more efficiently, 
have been well documented. Yet there remain several grand design challenges.  Materials 
that can act as potent immunostimulators, immunomodulators or both and can be 
processed into nano or microparticles that can safely deliver antigens and TLR ligands to 
APCs are still being studied to determine their efficacy in humans. Similarly, particulate 
systems that are broadly applicable to a variety of diseases and therapeutics and can be 
delivered through multiple routes need to be developed. It is also critical for the field to 
study the fundamental mechanism of particulate vaccines, especially how these carriers 
are internalized and transported in-vivo, which types of immune cells interact with these 
carriers and where etc.  Intravital molecular and cellular imaging should play a key 
collaborative role in gathering this critical information, which would then allow rational 
design of carriers. While there are myriads of factors to consider when developing an 
immunotherapy, there is an almost equally large repertoire of tunable polymers and 
delivery strategies to meet the needs of any given system. Together with the constantly 
advancing fields of antigen and adjuvant development, particulate vaccine systems are 
likely to be at the forefront of immunotherapeutics for bacterial and viral infections alike 
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CHAPTER 3  AIM 1 
FABRICATION AND EVALUATION OF MICRO- AND NANO-PLPS 
IN IN VITRO MURINE DC CULTURE SYSTEMS 
In nature, pathogens come in varying sizes, from small (< 100 nm) and large (200-400 
nm) viruses to bacteria and other parasites (~1-2 microns or larger). It is well established 
that viruses and bacteria elicit different types of host immune responses; the fundamental 
mechanisms of which are still being elucidated 141–144. However, most research to date 
has focused on pathogen associated molecular pattern (PAMP) induced signaling 
mechanisms, such as TLR activation.  Concurrently, biomaterial-based, particulate 
vaccine formulations designed to mimic pathogens are being widely investigated for 
delivery of antigens and PAMPs 145–147 to study prophylactic and therapeutic immune 
responses against infectious diseases, autoimmune disorders, or tumors. These 
formulations are thought to interact primarily with DCs at the site of administration or 
within the draining lymph nodes (dLNs). However, few studies have investigated how 
physical properties of pathogen-like carriers (e.g. size, ligand density, etc.) affect their 
tropism to various dendritic cell (DC) subsets. 
Bone marrow derived dendritic cells have been heavily used in vitro to predict how 
vaccine formulations will perform in in vivo experiments. However, production of these 
cells in vitro is not standardized across the field and is, in fact extremely variable from 
publication to publication. Moreover, it is typical for a study to perform in vitro 
experiments on cells from only one culture protocol, sometimes without even 
characterizing the cells on which the experiment is being performed. 
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Inaba et al. established one of the first protocols for generating over 70% CD11c+ 
dendritic cells from the bone marrow of mouse leg bones using granulocyte-macrophage 
colony stimulating factor (GMCSF) to promote the DC phenotype148. In addition to 
GMCSF, other growth factors have been used to induce high yields of immature DCs that 
are responsive to common pathogenic stimuli. Interleukin 4 (IL4) is frequently added to 
bone marrow cultures as studies have historically correlated it with maturation and 
production of Type 1 Helper T cells promoting cytokines149. Dendritic cells that are 
produced using these cultures resemble conventional, migratory DCs that are found in the 
periphery and have a high capacity for antigen presentation. It has also been shown that 
the effects on DC phenotype induced by the addition of IL4 to a GMCSF supplemented 
culture system are temporally dependent150. Most recently, it has been determined that 
IL4 also reduces the growth of macrophage-like cells in bone marrow derived cultures151.  
Recently this notion that IL4 produces the best DC culture system in vitro to test antigen 
presentation and Th1 polarization has been challenged. Gao et al. discovered a population 
of DCs that express IRF4, which has been implicated in regulation of many types of 
immune cells and prevents important inflammatory responses such as skin DC migration 
to lymph nodes and TLR-induced gene expression in macrophages. They found that 
expression of PDL2 is also associated with this cell type and that IL4 promoted PDL2 
expression. Gao et al. were also able to show that these PDL2+ cells that were regulated 
by IRF4 did not respond to TLR agonists, likely due to reduced endocytic activity75.  
Another important DC phenotype that has been developed in vitro is the plasmacytoid 
dendritic cell. Unlike conventional dendritic cells, plasmacytoid DCs are not as efficient 
at antigen presentation. However, their role in promoting a Th1 response has been 
realized. They highly express TLR7 and TLR9, making them very sensitive to microbial 
infection152. In response, these cells secrete large amounts of IFN-α, which promotes Th1 
cytokine production153. These cells can be isolated from mouse spleens in reasonable 
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quantities and techniques have also been developed to culture them from bone marrow 
using Fms-like tyrosine kinase 3 ligand (FLT3L)1,153–155. 
In this aim, we strive to fully characterize the culture system in which we test our vaccine 
formulations as well as elucidate how treatment of cells with different growth factors can 
affect cell phenotype and ultimately, interaction with particulate vaccines. 
At the same time, we have developed particulate formulations to test whether a 
fundamental particle parameter (i.e. size) can be utilized to passively target specific DC 
subsets and modulate downstream immune events while all other vaccine properties 
(antigen/adjuvant dose, particle dose, etc.) were kept constant. Using these two systems 
together, we were able to determine whether particle size plays a significant role in 
programming DC phenotype and subsequent T cell maturation in vitro.  
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3.1 METHODS  
3.1.1 Materials  
Acid end-capped PLGA RG502H (MW 7,000-17,000) and poly (vinyl alcohol) (PVA, 
MW 31,000) was purchased from Sigma-Aldrich (St. Louis, MO). Sulfo-NHS and EDC 
used for conjugation chemistry were from Pierce (Life Technologies, Grand Island, NY). 
Polyethylenimine (PEI, branched, MW 70,000) was purchased from Polysciences Inc. 
(Warrington, PA). Unmodified CpG oligiodeoxynucleotide (ODN) 1826 (5’-
tccatgacgttcctgacgtt-3’) was purchased and characterized by OligoFactory (Holliston, 
MA) and contained negligible amounts of endotoxin. Fluorescent CpG (Alexafluor 647) 
was custom-made by Integrated DNA Technologies (Coralville, IA). Endotoxin-free 
ovalbumin (OVA) was from BioVendor (Ashville, NC). Ribogreen and BCA assays (Life 
Tech) were used to quantify CpG and OVA, respectively. All antibodies were purchased 
from either Ebioscience or Biolegend (San Diego, CA). ELISA Ready-Set-Go kits were 
purchased from Ebioscience. 
3.1.2   Mice and primary cell isolation 
 The use of animals was approved by The Institutional Animal Care and Use Committee 
(IACUC) at Georgia Institute of Technology (Atlanta, GA). Female (4-5 weeks) 
C57BL/6 mice were purchased from Jackson Labs. Experiments were conducted when 
mice were between 5-8 weeks old.  
For bone marrow derived cells, mouse long bones (femur and tibia) were collected and 
cleaned of skin and muscle tissue. Bone marrow was flushed with cold PBS using a 28-
gauge needle and syringe. Red blood cells were lysed and remaining cells were cultured 
in dishes at 5*105 cells/ml of medium. Medium consisted of RPMI 1640 + 10% heat-
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inactivated characterized FBS + 1% Penicillin/Streptomycin + 1mM sodium pyruvate, 
1% non-essential amino acids and 1x beta-mercaptoethanol. Cell cultures were also 
supplemented with 20ng/uL of granulocyte-macrophage colony stimulating factor 
(GMCSF) and 10ng/uL of interleukin 4 (IL4) throughout the course of the culture. 
Medium was refreshed every other day for 7 days, at which point loosely adherent cells 
were removed and replated for use in in vitro evaluation of particle formulations. Cells 
were sometimes sorted using a Pan Dendritic Cell Isolation magnet activated cell sorting 
(MACS) kit (Miltenyi Biotec, San Diego, CA) to enrich the mature DC population 
(CD11c+CD11b+). Purity following sorting was above 95%. 
Splenic DCs were isolated from whole spleens of C57 black mice. Spleens were cut into 
pieces and incubated with collagenase D (2mg/ml) for 1 hour. Splenic tissue was then 
mashed through a cell strainer and lysed of its red blood cells. Plasmacytoid DCs were 
isolated using a Plasmacytoid Cell Isolation kit MACS kit (Miltenyi). Purity following 
sorting was above 80%.  
3.1.3 Synthesis of micro- and nano- PLGA particles with polyethylenimine 
conjugation 
PLGA microparticles were prepared using a water-oil-water double emulsion (W/O/W), 
solvent evaporation method as previously published156–158. Briefly, 200 mg PLGA 
(Resomer 502H) was dissolved in 7ml dichloromethane (DCM) and added to 300uL of 
filtered water. The first emulsion was homogenized at 10,000 RPM for 2 minutes. The 
first emulsion was then added to 1% polyvinyl alcohol (PVA) and homogenized again for 
2 minutes (10000 RPM). DCM was allowed to evaporate from W/O/W emulsion for ~3.5 
hours and particles were washed several times with water. PLGA nanoparticles were 
 36 
fabricated using a similar method with slight modifications. Specifically, PLGA was 
dissolved in dichloromethane (DCM) at 5% w/v and 1ml of water was added to form the 
first emulsion. The first emulsion was then sonicated using a probe sonicator (VibraCell, 
CT) at 85W for 2 minutes at room temperature and added to 16ml of 5% PVA to form the 
second emulsion. This emulsion was then sonicated at 85W for 5 minutes, followed by 
constant stirring for ~3 hours to allow for solvent evaporation. Nanoparticles were 
collected and larger particles were size excluded using centrifugation. The smaller 
particle population was then collected at 20,000 xg, washed 3 times with deionized water 
and lyophilized.  
Particles were then covalently surface modified with branched PEI using EDC/sulfo-NHS 
linker chemistry, which has been described previously. Particle size and zeta potential 
was determined using a Zetasizer Nano ZS (Malvern, MA).     
3.1.4 CpG/OVA loading on PEI-PLGA particles 
All molecules were loaded onto particles in a DNase/RNase-free sodium phosphate 
buffer (pH 6). Dried particles were weighed out and resuspended at 1mg/100uL loading 
buffer. Suspensions were vortexed and sonicated to break up aggregates. For PLPs loaded 
with only CpG, CpG was diluted to 13ug/900uL loading buffer. The particle suspension 
was then added, drop-wise, to the CpG solution while vortexing. Loading was allowed to 
proceed overnight at 4°C. Particles loaded with only OVA were loaded in presence of 
50ug/ml ovalbumin overnight at 4°C. Particles that were loaded with OVA+CpG were 
loaded with OVA first, using the overnight protocol above. CpG was added the following 
day and left to load on OVA-loaded particles for 4 hours at 4°C. Ribogreen and BCA 
assays were used to determine loading levels of CpG and OVA, respectively.   
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3.1.5 Microscopy of PLPs 
Particles were characterized using scanning electron microscopy (e.g. size, morphoplogy) 
and structured illumination microscopy (e.g. dual loading of antigen and adjuvant).  
For SEM, particles were suspended in filtered water and pipetted onto carbon paper 
attached to an SEM stud, where they were allowed to dry overnight. Studs were coated 
with a 10nm layer of gold to enhance conductance using a spin-coater. Samples were 
then imaged using InLens imaging.  
For SIM microscopy, samples were dual loaded with fluorescent CpG (FITC) and 
fluorescent OVA (Alexafluor 647) together. Particles were washed and resuspended in 
PBS then pipetted onto a glass slide. A coverslip was applied over the samples before 
imaging.  
3.1.6 Dendritic cell uptake 
After 7 days of culture, loosely adherent BMDCs were sorted, replated and treated with 
particle formulations. Fluorescent CpG was given at 5ug/106 cells (~385ug PLGA 
particles) and was kept constant for all delivery formats. Cells were allowed to interact 
with formulations for 24 hours, after which they were collected. Analysis was performed 
using an Accuri C6 flow cytometer. Gating was determined using fluorescence readout of 
untreated cells.  
3.1.7 Dendritic cell activation evaluation – flow cytometry 
After 7 days of culture, loosely adherent BMDCs were replated and treated with particle 
formulations. CpG was given at 5ug/106 cells (~385ug PLGA particles) and was kept 
constant for all delivery formats. Cells were allowed to interact with formulations for 24 
hours, after which they were collected. Cells were washed and blocked to prevent non-
specific interactions with Fc antibody portions (anti-CD16/CD23, Ebioscience). Cells 
were then stained using anti-CD11c-APC, anti-CD86-FITC, anti-PDL2-FITC/PE, anti-
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PDL1-PE-Cy7 and/or anti-CD40-PerCp-Cy5.5 and analyzed on an Accuri C6 flow 
cytometer (BD Biosciences). Gating was determined using isotype controls.  
3.1.8 Dendritic cell activation evaluation – intracellular staining 
After 24 hours of treatment, cells were washed and stained for extracellular markers as 
described above. Following initial staining, cells were fixed with Cytofix buffer (BD 
Biosciences) for 10 minutes at RT. Cells were then washed using Perm/Wash Buffer (BD 
Biosciences) and stained (in Perm/Wash) with anti-IL10-PerCp-Cy5.5 and anti-IL12p70-
APC. After suitable incubation, cells were washed with Perm/Wash buffer and 
resuspended in FACS buffer (0.5% BSA in PBS) and analyzed using an Accuri C6 flow 
cytometer.  
3.1.9 Dendritic cell activation evaluation – ELISA cytokine analysis 
After 24 hours of treatment, cells were removed and supernatant collected for analysis 
using ELISA. These assays were performed to determine IFNγ, and IFNβ protein 
concentrations in cell supernatant. IFN assays were also performed following 48 hours of 
particle treatment.  
3.1.10 Dendritic cell activation evaluation – Antigen presentation 
For studies of antigen presentation, cells were treated with 10ug of soluble OVA in 
addition to CpG formulations for 24 hours. Antigen presentation was determined in two 
ways. The first was staining using anti-MHC I-SIINFEKL and was analyzed using an 
Accuri C6 flow cytometer. 
Another method of determining antigen presentation efficiency is a mixed leukocyte 
reaction. For these experiments, DCs were cultured for 24 hours with OVA alongside 
CpG formulations then added to a co-culture system with CD4 or CD8 T cells isolated 
from OVA-specific transgenic mice (OTII and OTI, respectively) and a 1:2 DC:T cell 
ratio. Supernatant and cells were collected either 24 or 72 hours later. T cells were then 
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stained for early activation markers (i.e. CD25) or regulatory T cell markers (i.e. Foxp3) 
and analyzed using flow cytometry. Supernatant was analyzed for cytokine content, 
specifically IFNγ, IL4 or IL2 (ELISA).  
3.1.11 Statistical Analysis 
Student’s t-test was used to perform statistical analysis between two groups, where 
p<0.05 was considered significant. In vitro experiments were conducted a minimum of 





3.2.1 Characterization of pathogen-like particles (PLPs) 
Characterization of PLPs (i.e. size, zeta potential, maximum loading of CpG) is 
summarized in Table 4. In order to test the influence of formulations size, it must be 
ensured that the formulations being compared are disparate enough in size. Figure 4 
indicates that there is minimal overlap of the two formulations chosen for this study, with 
average micro-PLP size at ~1.18um and nano-PLPs averaging at ~280nm. This was 
further validated using scanning electron microscopy (Figure 5). Additionally, PEI 
conjugation was optimized to ensure that surface charge was similar (~32mV) and 
provided sufficient cationicity to load a variety of relevant molecules, including larger 
protein and small oligos ( 
Figure 6). We were also able to demonstrate dual loading of antigen and adjuvant 
molecules simultaneously on the same particle (Figure 7).  
 
 
Table 4: PLP Characterization 
	   Size	   Zeta	  before	  loading	   Zeta	  after	  loading	   Max	  Load	  
Micro	   1.18	  +/-­‐	  0.28	  um	   36.7	  +/-­‐	  3.73	  mV	   -­‐24.2	  +/-­‐	  8.7	  mV	   13ug/mg	  
	   	   	   	   	  
















Figure 4: PLP size - Particles were measured using dynamic light scattering. Peaks show 











Figure 5: SEM of nano-PLPs - Scanning electron microscopy validates DLS size 




































Figure 6: PLP loading capacity - Both micro- and nano-PLPs were capable of loading 











































































Figure 7: Dual loading of OVA+CpG on nano-PLP - FITC-CpG and AF647-OVA were 
loaded simultanously on nano-PLPs and images used SIM microscopy.  
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3.2.2 Development of DC subset cultures 
The culture system that has been extensively used in the Roy lab over the last decade 
involves isolation of bone marrow from naïve, female mouse femurs and tibias. After red 
blood cell lysis, the remaining cell population is cultured in medium supplemented with 
20ng/ml murine GMCSF and 10ng/ml murine IL4. These cytokines were replenished 
with media changes every other day for the total 6 days of culture. At Day 6, cells were 
stained for common DC maturation markers including CD11c, PDL2, CD11b, MHCII 
and CD86. We have used this system to extensively test the effect of various TLR 
ligands, both soluble and attached to micro- and nano-PLPs. While we have consistently 
observed size effects, we soon identified the variability of cells within these cultures, 
making it impossible to correlate effects with a specific cell phenotype (Figure 8). We 
later also compared our results to a system without IL4 and to the system used by Gao et 
















Figure 8: BMDC Characterization of GMCSF+IL4 Culture - We observed that cells 
originating from isolated bone marrow progenitors were heterogeneous and included a 































This allowed us to test the differential expression of maturation markers induced by IL4 
given in two temporally different fashions. CD11c, the identification marker for dendritic 
cells in mice, was highly expressed (between 60-70%) in all culture systems and 
therefore this population was gated to determine marker expression on CD11c+ cells 
exclusively. CD11b was also highly expressed (over 85%) in all systems. Interestingly, 
our system seems to induce more spontaneous maturation (indicated by higher levels of 
MHCII and CD86) than the Gao method and when cultures were only supplemented with 
GMCSF (Figure 9). More importantly, it is demonstrated here that the addition of IL4 in 
both cases significantly increases the expression of PDL2 and presumably the potential 




















Figure 9: Characterization of DC expression profiles with and without IL4 
supplementation. Classic DC markers were analyzed after 6 days of culture with only 
GMCSF, GMCSF+IL4 and GMCSF with a burst of IL4 only on Day 5. IL4 (both 
constant and burst) drastically increased the expression of PDL2 and also CD86. This 





























Based on these results, we decided it is important to separate the PDL2+ and PDL2- 
populations to differentiate their contributions to cytokine secretion and T cell maturation 
in our system. To do this, we cultured our cells using the aforementioned technique 
including IL4 and sorted, using fluorescence activated cell sorting (FACS), the PDL2+ 
from the PDL2- populations (>95% purity). These populations were then used to test how 
TLR agonist stimulation affects their maturation and cytokine secretion.  
We were also interested in investigating the interaction of our vaccine formulations with 
plasmacytoid DCs. For these studies, we isolated the spleens of naïve, female mice and 
using the Miltenyi Plasmacytoid Isolation Kit (negative sort), sorted out 
CD11c+B220+Ly6C+ cells (Figure 10). 
 
Figure 10. Spleen isolated pDC purity - Plasmacytoid DCs were isolated from spleens of 
naïve mice by sorting using a Plasmacytoid DC Isolation kit (Miltenyi). Purity of the cell 




3.2.2.1 PDL2+ DCs – Spontaneous maturation vs induced expression 
It has been shown in the literature that mechanical disruption of immature DC clusters 
formed during differentiation leads to nonspecific maturation that is mediated by the β-
catenin pathway rather than the typical TLR-L induced NF-κB pathway. While these 
cells to have upregulated expression of costimulatory markers on their surface, they do 
not secrete inflammatory cytokines and therefore promote a immunosuppressive T cell 
phenotype rather than an effector phenotype159. This can be triggered simply by pipetting 
the cells for replating or by sorting using magnetic columns. For example, in our hands 
the PDL2+ cell population increases significantly after replating without any other 
stimulation (Figure 11). This population, going forward, will be referred to as induced 
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3.2.3 DCs show size preference in vitro 
After cultures were appropriately characterized, we began to investigate how each of 
these DC subsets of interest interacts with our PLP formulations. First, we quantified 
uptake of PLPs carrying fluorescent CpG. To properly evaluate preference, we cultured 
mixed populations of PDL2+ and PDL2- cells with soluble fCpG, micro-PLPs or nano-
PLPS for 24 hours. Our first observation was that PDL2+ and PDL2- cells showed 
opposite preference towards PLP formulations. PDL2+ cells took up significantly more 










Figure 12: BMDCs exhibit size-dependent preference for PLPs in a PDL2 dependent 
manner. PDL2+ cells took up significantly more micro-PLPs than either nano-PLPs or 
soluble formualtions. PDL2- cells, on the other hand, took up nano-PLPs and soluble 












































Furthermore, we observed that CpG-PLP+ cells took up similar amounts of CpG, 
regardless of PLP size. Therefore, dose of CpG per cell is largely the same, despite 
particle number and PLGA dose per cell varying (Figure 13). When we performed similar 
experiments on plasmacytoid DCs, we validated that this subset also demonstrates a 




















































































































Also similar to BMDCs, pDCs also take up a comparable amount of CpG regardless of 











Figure 15: pDCs take up similar amounts of CpG regardless of PLP carrier. It was also 






























3.2.4 DC activation is modulated in a PLP-size dependent manner 
DC activation is evaluated based on signals that are required for them to effectively 
induce T cell maturation. These signals include upregulation of co-stimulatory molecules 
present on the DC cell membrane, secretion of pro-inflammatory (or anti-inflammatory) 
cytokines and presentation of peptide-MHC complexes. Here we evaluated each of these 
to determine whether DC activation signals were affected by PLP size.  
3.2.4.1 PLPs promote differntial expression of co-stimulatory molecules 
Multiple molecules promote co-stimulation of T cells during antigen presentation. As 
described previously, these include CD86/CD80, which engage T cell CD28, promoting 
immune synapse formation. Additionally, CD40 (a TNF receptor) is also expressed 
following DC maturation. PDL2+/PDL2- DC expression profiles of CD86 followed 
uptake patterns. PDL2+ cells increased expression of CD86 following treatment with 
micro-PLPs and this response was abrogated by nano-PLPs treatment. The inverse 
expression pattern was observed in PDL2- cells (Figure 16, left). CD40 expression did 
not follow a similar pattern, but instead was expressed similarly regardless of PLP 
treatment (Figure 16, right).  Average expression of CD86 or CD40 per cell (mean 





Figure 16: DC co-stimulatory molecule expression varies with PLP size. PDL2+ cells 
become more activated (based on CD86 expression) after stimulation after treatment with 
micro-PLPs. PDL2- cells exhibited an opposite expression pattern. CD40 expression did 




































































































































































































 Interestingly, despite plasmacytoid DC’s preference for micro-PLPs, we observed that 
they are activated more efficiently (i.e. expression of CD86) by nano-PLP (Figure 18, 
left). However, the average expression of CD86 per cell did not vary based on PLP 












Figure 18: A greater percentage of pDC population expresses CD86 after treatment with 




































































3.2.4.2 DC secretome indicates size-dependent programming 
The presence of pro-inflammatory cytokines is essential to promote effector T cell 
function. In the absence of cytokines, T cells receiving antigenic signals from DCs will 
either become anergic or apoptose. This mechanism regulates self-reactive T cells and 
promotes tolerance160. Additionally, DCs produce anti-inflammatory cytokines as 
negative feedback for immune response generation to prevent autoimmunity or immune 
over-activity161,162. Therefore, the ratio of pro-inflammatory to anti-inflammatory 
cytokines present during T cell maturation will critically affect the resultant 
effector/regulatory response.  
IL12p70, one of the main pro-inflammatory DC cytokines, is known to promote effector 
T cell activity and can be induced by TLR engagement and signaling163,164. TLR 
signaling also promotes production of IL10, a regulatory, anti-inflammatory 
cytokine165,166. Therefore, we analyzed the ratio of these two cytokines to determine the 
phenotypic state of our DC subsets.  
Our first observation was that PDL2- cells do not produce detectable levels of cytokine, 
making PDL2+ cells the primary cytokine-secreting cells in GMCSF+IL4 culture 



















































PDL2+ cells were able to produce IL12p70, IL10 upon stimulation. Interestingly, the 
ratio of IL12p70:IL10 production varies significantly with delivery format. We observed 
that treatment with micro-PLPs promoted a pro-inflammatory dominated cytokine 
profile, with IL12p70 being produced in around 4 times more PDL2+ cells. This 
dominance was less pronounced in cells treated with nano-PLPs and almost completely 













Figure 20: IL12p70:IL10 in PDL2+ cells. PDL2+ cells treated with mPLPs exhibit a pro-
inflammatory dominated program. Nano-PLPs induce greater production of anti-


































In addition to these cytokines, CpG is known to also promote interferon (IFN) production 
in DCs. Type 1 IFN (IFNα/β) are associated with anti-viral immunity and can promote 
type 1 polarization in both DCs, cytotoxic T cell development and natural killer cell 
activation167. Type 2 IFNs (IFNγ) are known to be very important for type 1 T cell 
effector function, but have also been shown to promote pro-inflammatory signaling in 
DCs as well168. We therefore also looked at the expression levels of this class of 
cytokines in PDL2+ DCs.   
We found that, while PDL2+ cells do produce a significant amount of IFNγ by 24 hours 
after CpG dosing, especially when treated with soluble or micro-PLP delivered CpG. 
However, there is a significant reduction of IFNγ associated with nano-PLP delivered 
CpG. Interestingly, levels of IFNγ are indistinguishable from untreated samples 48 hours 
after treatment (Figure 21). This validates that DCs use this cytokine as an autocrine 
signal, potentially to promote subsequent pro-inflammatory signals. IFNα was 
undetectable in these cultures, but IFNβ was produced at low levels (Figure 22). It’s 
possible that the kinetics of IFNβ production are much faster and that, at 24 hours, much 
of it has already been consumed. Overall, this data suggests that PLP-size directs 
programming and promotes unique functions. Specifically, micro-PLPs induce an 





















Figure 21: PDL2+ cell production of IFN-gamma. PDL2+ cells produce significant 
amounts of IFN-gamma, especially when treated with soluble or micro-PLP delivered 
CpG. However, it is consumed over the next 24 hours, as indicated by the drop to 











































































3.2.5 PLP size-dependent DC programming influences T cell maturation 
The primary function of activated DCs is to present antigen to T cells, alongside 
activation signals, to promote antigen-specific T cell proliferation and effector activity. In 
order to evaluate the ability of DCs to promote antigen-specific T cell maturation, we 
employed a mixed leukocyte reaction technique. Antigen-specific T cells were isolated 
from spleens of transgenic mice whose T cells are engineered to recognize specific OVA 
epitopes. These cells were cocultured with DC pulsed with whole OVA protein alongside 
CpG formulations. Our first indication that T cells were receiving sufficient maturation 
signals from primed DCs was T cell upregulation of an early activation marker, CD25.  
First, as we suspected, PDL2- cells were not able to induce T cell activation, likely due to 












































































However, PDL2+ DCs were able to promote increased expression of CD25 after one day 
of coculture with either CD4+ or CD8+ T cells. Micro-PLPs induced the most potent 
upregulation of CD25 in CD8+ T cells, which was likely due to increase pro-
inflammatory signals provided by DCs in this group (Figure 24, left). While soluble CpG 
induced the most robust activation of CD4+ T cells, micro-PLPs-DCs still outperformed 

































































































When T cells mature into effector phenotype, they become efficient producers of 
immunomodulatory cytokines, especially IFNγ, IL4 and IL2. IFNγ is secreted by cells of 
a type 1 phenotype and promotes the proliferation of CD8+ cytotoxic T cells and 
antibody class switching to those isotypes with greater antibody dependent cell-mediated 
cytotoxicity (ADCC) efficiency169,170. On the other hand, IL4 is implicated in type 2 T 
cell effector activity and IgG1 antibody production171. IL2 is important for T cell 
maintenance and persistence of T cell effector function172. 
After 3 days of co-culture with primed PDL2+ DCs, T cell supernatant was removed and 
analyzed for the cytokines discussed above. Both CD8+ (OTI) and CD4+ (OTII) cells 
produced significant amounts of IFNγ, especially when cultured with DC primed with 
either soluble or micro-PLP delivered CpG. Interestingly, DCs treated with nano-PLPs 











Figure 25: PDL2+ DCs primed with soluble CpG or micro-PLPs induced IFNγ 





































































Inversely, T cells that were co-cultured with soluble CpG-DCs did not produce more IL4 
than those cultured with untreated DCs. Micro-PLP-DCs promoted a small amount of IL4 
production in both CD8+ and CD4+ T cells, but nano-PLP-DCs induced significantly 
more (Figure 26). This inverse trend mirrors cytokine signals observed in DC themselves 










Figure 26: PDL2+ DCs primed with nano-PLPs induced IL4 production most efficiently 












































































Interestingly, for PDL2+ DC co-cultures, all treatments caused CD8+ T cells to produce 
IL2 at similar levels and none of the formulations induced IL2 efficiently in CD4+ cells 
(Figure 27). However, when CD4+ T cells were co-cultured with pre-primed pDCs, only 
those treated with nano-PLPs promoted any IL2 production (Figure 28). This finding 
implies that enhanced activation that was associated with nano-PLP delivery of CpG to 























































































































Finally, it is known that DCs are able to provide signals to T cells that support 
differentiation of regulatory T cells, responsible for prohibition of effector T cell function 
and providing an internal control for the immune response173. Consistent with tolerogenic 
cytokine profiles of PDL2+ DCs treated with nano-PLPs, these DCs also promoted 
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3.3 DISCUSSION 
Particle biomaterial-based vaccine formulations are being widely investigated for 
delivery of antigens and adjuvants. It is our current understanding that tissue–resident 
antigen presenting cells, most notably dendritic cells (DCs) take up vaccine-carrying 
particles at the site of injection, become activated then migrate to draining lymph nodes 
where they modulate the cellular immune response. While it is now well appreciated that 
many subsets of DCs reside in peripheral tissues and can uniquely direct immunity, little 
is known about whether particle formulations preferentially target particular DC subsets 
and/or whether this can be used to specifically modulate the resultant immune response.  
For this work, we’ve designed a modular particle platform (pathogen-like particles, 
PLPs) that can be used to test a large variety of variables. We can easily tune PLP size 
and charge, as well as load a large variety of antigen and adjuvant molecules both inside 
(encapsulated) and on the surface of the particles156,157,174,175. This tunability provides us 
with a system that can be used to mimic natural pathogens and study how physical 
parameters play a role in modulating immunity. Specifically, this works proposes the use 
of a physical parameter (i.e. size) of particular vaccine carriers as a means of targeting 
specific peripheral dendritic cell populations. 
The immunological significance of particle size has been widely studied and also 
disputed (recently reviewed by Leleux et al. and Oyewumi et al)145,176. While it has been 
established that particles must be under 10um to allow phagocytosis and preferably under 
about 5um to be immunogenic, there is still debate over whether nanoparticles (NPs) 
under 1um or microparticles (MPs) between 1-5um are better for immunotherapy177. NPs 
under 100nm in diameter can travel through the lymphatic vessels to lymph nodes where 
they can carry out immunomodulatory tasks128. However, studies using particles that are 
intended for DC uptake at the site of injection have shown efficacy across particle sizes. 
This is likely due to DC ability to take up both viral and bacterial pathogens in the body, 
which range in size from 10nm to a few microns. While most of these studies concerning 
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particle size draw conclusions about which generates a more robust immune response, 
there have been no studies analyzing DC subset preference and the resultant effects on 
immunity. 
Our in vitro data demonstrate that there is a DC-phenotype dependent preference of 
microparticles or nanoparticles and we have convincingly demonstrated that this 
preference can affect eventual T cell immune modulation. T cells are essential for both 
elimination of infected or cancerous cells (CTLs) and induction of B cell maturation and 
antibody production. Therefore, size-driven effects at the DC level have the potential to 
alter the overarching immune response towards a particle vaccine, making this finding 
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CHAPTER 4  AIM 2 
VALIDATE EFFICACY OF PLP FORMULATIONS IN VIVO 
Despite success in vitro, translation is the eventual goal of all vaccine delivery platforms, 
the success rate of which has been grave, especially in clinical trials. The first step to 
translation is adapting the vitro models used to screen vaccines to small animal in vivo 
models to determine whether the same effects are observed in live animals. In this aim, 
we tested vaccine formulations that have been successful in inducing in vitro DC 
activation and antigen presentation. We have demonstrated that particle parameters such 
as size significantly influence (a) the ability of APCs to take up particles and travel to 






The use of animals was approved by The Institutional Animal Care and Use Committee 
(IACUC) at Georgia Institute of Technology (Atlanta, GA). C57BL/6 mice (female, 4-5 
weeks) were purchased from Jackson Laboratories (Bar Harbor, Maine). Antibodies were 
purchased from Ebioscience or Biolegend (San Diego, CA). Multi-plex mouse cytokine 
kits (8-plex) were purchased from Bio-rad (Hercules, CA). Cyrosectioning prep materials 
(OCT medium, cryomolds, glass slides) were purchased from Fisher Scientific (Waltham, 
MA).   
4.1.2 Particle distribution and DC subset analysis of draining lymph nodes 
Female C57BL/6 mice (5-6 weeks) were injected subcutaneously with 20ug of either 
soluble or particle-delivered Alexa-647-CpG. Control mice were given saline injections. 
Injections were performed either one day, five days or seven days prior to lymph node 
isolation. Mice that were given injections seven days prior to isolation were also given a 
booster injection one day prior to isolation to evaluate the effect of boosting.  
Inguinal lymph nodes were isolated and processed into a single cell suspension or frozen 
for cryosectioning. Processed cells were then stained with anti-mouse FITC-Ly6C, anti-
mouse FITC-CD86, anti-mouse FITC-CD103, anti-mouse PE-PDL2, anti-mouse PE-
Langerin, anti-mouse PE-CCR7 and anti-mouse PE-Cy5 CD11c. Cells were washed, 
resuspended in FACS buffer and analyzed using a BD Accuri C6 flow cytometer.  
Lymph nodes kept for cryosectioning were dried of excess liquid then snap frozen in 
OCT medium in liquid nitrogen. Cryosectioning was performed by the Yerkes Pathology 
Lab (Emory University, Atlanta, GA) or the Winship Cancer Institute Pathology Lab 
(Emory University, Atlanta, GA). Sections were blocked and incubated with primary 
antibodies (Biotin-CD3 and FITC-B220) overnight at 4°C. After washing, sections were 
stained with secondary antibodies (streptavidin-eFluor 570) for one hour, washed and 
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coverslips were mounted. Sections were imaged using a Zeiss LSM 700 Confocal 
Microscope.  
4.1.3 Immunization protocol 
Female C57BL/6 mice (5-6 weeks) were injected subcutaneously with either soluble or 
particle-delivered ovalbumin (10ug) and CpG (25ug). Ovalbumin and CpG were loaded 
onto the same particle for those groups. Control mice were given saline injections. Mice 
were given three injections at two week intervals. Lymphoid organs and blood were 
collected one week following the final injection.  
Lymph nodes and spleens were processed into single cell suspensions. Splenocytes were 
stained with FITC-CD8a, PE-NK1.1, PE-Cy7 CD3, APC-SIINFEKL-Class I tetramer, 
PE-CD4, PerCP-Cy5.5 Ly6G, PE-Cy7 CD11b, APC CD11c, APC-Cy7 CD25 and/or 
APC-Foxp3. Lymph node cells were stained with FITC-CD8a, PE-Cy7 CD3, APC-
SIINFEKL-Class I tetramer, PE-CD4, PerCP-Cy5.5 Ly6G, PE-Cy7 CD11b, APC CD11c, 
APC-Cy7 CD25, APC-Foxp3, FITC GL-7, and/or PerCP-Cy5.5 B220.  
Splenocytes were also restimulated with ovalbumin to determine cytokine section profiles 
of splenic antigen-specific T cells. Ovalbumin was given to cells at 200ug/106 cells for 72 
hours. Supernatant was collected for analysis using Bio-rad Bio-plex for mouse 
cytokines.  
Blood was centrifuged to pellet cells and serum was collected. IgG titers were assayed 
using ELISA for diluted serum samples.  
4.1.4 Immunohistochemistry staining 
Lymph nodes were isolated from vaccinated mice, rinsed with PBS and patted dry. They 
were then embedded within cyromolds filled with OCT freezing medium and snap frozen 
using liquid nitrogen. Sectioning was performed by the Yerkes Pathology Core (Emory 
University, Atlanta, GA). 
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4.1.5 OVA-B16 Melanoma survival study 
Mice were inoculated with 5*105 OVA-B16 tumor cells subcutaneously on Day 0. 
Vaccinations were then given at Day 11, 18 and 25. Lymphoid organs and serum were 
collected for a percentage of mice on Day 29 for immunological analysis and the 
remaining mice were sacrificed according to tumor progression. Tumor size threshold 
was 1.5cm in any direction.  
4.1.6 Statistical Analysis 
Student’s t-test was used to perform statistical analysis between two groups, where 
p<0.05 was considered significant. In vivo experiments were conducted with n=6 to 





4.2.1 Micro-PLPs traffic more efficiently to draining lymph nodes 
Lymph nodes are split into functional zones, including a T cell zone where T cells are 
introduced to antigen and mature, and germinal centers, where T cells interact with B 
cells and antibody is secreted. Migratory cells must end up in one of these zones in order 
to modulate adaptive immunity. Alternatively, it has been shown that migratory cells can 
also hand off antigen to lymphoid resident cells, which reside in high numbers in the 
periphery, near sinuses45,46,50. We therefore first investigated the location within the 
lymph node of PLPs 24 hours after injection, using immunohistochemistry (Figure 30).  
Micro-PLPs were found in large amounts, both in the periphery of the lymph node and in 
the T cell zones. It is likely that particles found in T cell zones were brought there by 
migratory skin DCs. However, it is possible that peripheral particles were able to drain to 
the lymph node on their own, similar to the observations made by Gerner et al. 50. Nano-
PLPs were found in T cell zones as well, but in significantly fewer numbers than micro-
PLPs, indicating their either do not induce DC migration as efficiently and/or cannot 












Figure 30: Micro-PLPs traffic to draining lymph nodes more efficiently at 24 hours. 
(left) Micro-PLPs are found in both the periphery (i.e. sinuses) of the lymph nodes as 




4.2.2 Migratory DCs carry CpG-PLPs to draining lymph nodes from skin 
Once we validated that PLPs could be found in the draining lymph node, we wanted to 
analyze the migratory population responsible for their trafficking with more granularity. 
To do this, we isolated lymph nodes 24 hours after subcutaneous immunization with 
PLPs carrying fluorescent CpG (or soluble fCpG) and stained them for multiple DC 
subsets found in the skin. These included PDL2+ dermal DCs, CD103+ dermal DCs, 
Langerhans cells, monocyte-derived inflammatory DCs and plasmacytoid 
DCs34,55,69,73,75,76,178. One day following injection, all of these cell types appeared in 
draining lymph nodes in varying percentages. Additionally, all of these subsets had a 
percentage of fCpG+ cells, indicating they are all responsible for transporting CpG to a 
certain degree (Figure 31). Migratory DCs that made up the largest CpG-carrying 
populations were PDL2+ dermal DCs and monocyte-derived inflammatory DCs. These 
two populations made up over 80% of cells that were CpG+ in the draining lymph nodes 
in mice treated with soluble CpG or micro-PLPs. Interestingly, both of these populations 
were found in significantly fewer numbers in lymph nodes of mice treated with nano-
PLPs. This could be related to PDL2+ cells’ preference for micro-PLPs (observed in 
vitro). CD103+Langerin+ cells were found in appreciable amounts as well and also 
seemed to prefer soluble CpG and micro-PLPs over nano-PLPs. Langerhans cells were 
found in small amounts at this time point. Finally, while plasmacytoid DCs made up a 
small portion of the total CpG carriers in the lymph nodes, they were found in 
significantly higher numbers in mice treated with nano-PLPs. This finding also correlates 




Figure 31: Skin-resident migratory DCs carry CpG-PLPs to draining lymph nodes. 
PDL2+ dermal DC make up the majority of migratory DCs in the lymph node and 
therefore, are the primary carriers of CpG (PLPs), especially micro-PLPs. Monocyte-
derived inflamatory DCs also make up a large portion of CpG carriers and likely overlap 
with PDL2 expressing DCs. Interesting nano-PLPs do are carried most efficiently by 












































































































































































































While these findings were very interesting and are certainly important to early T cell 
maturation, it is also known that some DC subsets exhibit delayed migration kinetics, 
including Langerhans cells179,180. Therefore, we also isolated lymph nodes 5 days after 
initial injection, as well as 7 days after initial injection with a booster given on day 6. The 
three populations that seemed interesting 24 hours after injection (PDL2+ DCs, monocyte 
derived iDCs and pDCs) all exhibited similar kinetics over the course of the experiment 
(Figure 32). They all peaked at early time points and fell to what may be the baseline by 
day 5. Boosting was able to reactivate monocyte derived iDCs and pDCs, promoting a 
second wave of migration. However, PDL2+ DCs were only able to recover and migrate 
again after boosting in mice given soluble CpG. This could potentially be due to a 






Figure 32: Primary CpG-carrying DC migration kinetics. PDL2+ DC populations peak 
early then taper off by Day 5. Boosting promotes reinfiltration of PDL2+ cells in mice 
given soluble CpG only. Monocyte-derived iDCs, however, can be reactivated with 
boosting. Plasmacytoid DCs migrate more rapidly in groups treated with nano-PLPs, but 





Other skin DC subsets exhibited different migration kinetics. PDL2+ dermal DCs that 
were described previously in literature also express CD301b. We therefore split this 
population into CD301b+ and CD301b- subpopulations (Figure 33a-b). Interestingly, 
CD301b+ populations did make up a larger percentage of the CpG+PDL2+ population 
but did not vary at all with delivery format. Additionally, none of these formulations were 
able to restimulate cells to a migratory state with a boost. However, in CD301b- 
populations showed a distinct preference for soluble CpG and micro-PLPs and also 
exhibited a lack of restimulation after boosting with micro-PLPs. Langerin+ DC 
migration was delayed and did not peak until 5 days after injection (Figure 33 c-d). They 
also were not able to repopulate the lymph nodes after one boosting, but could possibility 
at a later time point. While there seemed to be a slight preference for micro-PLPs in 































Figure 33: Langerin+ DCs exhibit delayed migration kinetics. Similar to what has been 
described in literature previously, Langerin expressing DC (regardless of CD103 
expression) migration is delayed in comparison to other DC subsets. Specifically, these 
cell populations peak in the draining lymph node 5 days following initial injection. The 
PDL2+ DC subset described in literature also expressed CD301b. We therefore split this 
population into CD301b+ and CD301b- populations and did show differing kinetics in 



































































































































4.2.3 Immunological response to micro- and nano-PLPs 
Following activated DC migration (or activation of lymphoid resident DCs), these cells 
will interact with T cells by providing signals described previously. From there, T cells 
will mature, proliferate and perform effector functions. These include producing 
cytokine, interacting with B cells to promote antibody class switching and secretion, 
killing infected cells and/or regulating immune activity. Therefore, these functions are 
analyzed as outputs of an immunological response and can be correlated with vaccine 
efficacy. For these studies, we vaccinated mice with a model protein antigen (OVA) 
alongside CpG. Mice were given an initial injection followed by 2 boosters at 2 week 
intervals. Lymphoid organs (i.e. spleen and inguinal lymph nodes) and serum were 
isolated one week following the final injection.  
4.2.3.1 Lymph node – DC activation 
We first analyzed whether any of the vaccine formulations caused proliferation of lymph 
node resident DC populations. Specifically, we looked at total DCs (CD11c+ cells), as 
well as CD8α+ DCs and CD4+ DCs, which are known to activate T cells that share their 
surface markers (CD8 and CD4, respectively)17,49,181. We observed no significant 
difference in total DCs nor CD8+ DCs. However, there was a small increase in the 
presence of CD4+ DCs after vaccination with micro-PLPs (Figure 34).  
Figure 34: Only CD4+ DCs were enhanced by PLP vaccination, specifically with micro-

































































































































4.2.3.2 Lymph node - T cell response 
The first critical observation was that the PLP vaccines induce a CD4+ helper T cell 
dominated response in draining lymph nodes. Inversely, the soluble vaccine increased the 
percentage of CD8+ T cells over PLP vaccines (Figure 35).  
Figure 35: PLPs induce CD4 T cell dominated immunity. In mice treated with either PLP 
formulation, CD4+ T cells were dominant in draining lymph nodes. However, this shift 
was reversed in mice treated with soluble CpG, in which there was a significant increase 
in the CD8:CD4 ratio.  
 
Interestingly, when the CD8+ population was further subtyped for antigen-specificity, 
mice treated with PLP vaccines had significantly larger populations of antigen-specific 
cytotoxic T cells (Figure 36). This population was most enhanced in mice treated with 
nano-PLPs, where the antigen-specific populations were nearly twice as large as those in 
micro-PLP treated mice. This is consistent with an anti-viral response and potentially 
driven by the early increase in pDC migration. This finding was confirmed by MHC-I-
SIINKFEKL staining of DCs within the draining lymph nodes (Figure 37). Surprisingly, 
nano-PLPs also promoted the increase of regulatory T cell populations, both in the 









Figure 36: PLP vacciation results in more antigen-specific CD8+ T cells. In draining 
lymph nodes, there is a greater percentage of antigen-specific CD8+ T cells after 























































Figure 38: Nano-PLP vacciantion induces the upregulation of regulatory T cell 









4.2.3.3 Spleen – DC Activation 
Spleen DC populations were examined to determine whether there was a significant 
immunological response derived there. We observed no significant differences in DC 
populations between any treatment groups tested (Figure 39).  
 
 











































































































































































































4.2.3.4 Spleen – T cell response 
We also did not see any significant differences between total, CD8+ or CD4+ populations 
of T cells in any treatment groups. This is likely due to the relatively low antigen dose 
used for this vaccination scheme (Figure 40).  






















































































































































































Despite there being no effect of treatment on effector populations, splenic regulatory T 
cell populations were enhanced in both mice vaccinated with soluble formulations or 
nano-PLPs (Figure 41). This correlates with the regulatory response observed in the 















4.2.3.5 Spleen – Natural killer cell and NK-T cell response 
Natural killer cells and natural killer-T cells are two other cytotoxic cell types that aid in 
the removal of infectious cells182–185. Natural killer cell populations were increased after 
vaccination with PLPs and natural killer-T cell populations were enhanced in micro-PLP 
treated mice (Figure 42).  
 
 
Figure 42: NK and NK-Tcell responses are enhanced by PLP vaccination. The presence 
of NK cells in the spleen are promoted by PLP vaccination. Additionally, micro-PLP 








































































4.2.3.6 Spleen – T cell Cytokine Secretome  
To further characterize the T cell response, we restimulated splenocytes from vaccinated 
mice with whole ovalbumin antigen to evaluate their secretome. While there was no 
significant difference in the amount of IFN-γ produced by splenocytes from mice 
vaccinated with either PLP formulation, we observed a striking increase in the production 
of type 2 and anti-inflammatory cytokines, including IL4, IL5 and IL10 only in mice 
treated with nano-PLPs (Figure 43). Additionally, PLP formulations promoted greater 
production of IL2, indicating greater overall activation of T cell populations in PLP-
treated mice. According to these findings, PLPs generally promote greater T cell activity 
and offer size-dependent tunability of T cell phenotype.    
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Figure 43: Secretome of splenic T cells from each treatment group indicates differential T 












4.2.3.7 Lymph node – Germinal center formation 
One of the primary roles of helper T cells is to provide signals to lymphoid resident B 
cells to promote class switching of secreted antibodies. This occurs in the germinal 
centers of lymphoid organs. We were able to identify germinal center formation in all 
treated lymph nodes. However, staining for IgG revealed that only mice treated with 
PLPs had highly functioning, IgG antibody-secreting B cells present in their lymph nodes 
(Figure 44) This was confirmed by flow cytometry analysis, where only PLP-treated 
mice had significant populations of activated germinal center B cells (Figure 45). 
Figure 44: Only PLP vaccines induce IgG producing, germinal center B cells. All 
treatment groups induced the formation of germinal centers in lymph nodes. However, 
only lymph nodes taken from mice vaccinated with PLPs stained for IgG, indicating B 




























































4.2.3.8 Lymph node – Serum antibody titers 
To further investigate the functionality of these activated B cells, we measured antibody 
levels in the serum of vaccinated mice. Both PLP vaccines increased the production of 
IgG1 over soluble vaccines (Figure 46).  Strikingly, only mice that were treated with 
micro-PLP vaccines had high levels of IgG2c, which is associated with a type 1 cytotoxic 
response (Figure 47) and anti-bacterial immunity. Furthermore, we observed that serum 
cytokine content was indistinguishable from control mice treated only with saline (Figure 











Figure 46: PLP vaccination induces higher IgG1 titers than a soluble vaccine. 
 
























Figure 48: Serum cytokine levels are indistinguishable from saline control mice, 


















































































































































4.2.4 Therapeutic value of micro- or nano-PLPs against tumor challenge 
To determine whether the immunological response we observed previously has any 
therapeutic value, we challenged mice with an engineered melanoma cancer line (OVA-
B16 melanoma). Mice were inoculated with melanoma, followed by 3 injections of either 
soluble antigen (OVA) alone, micro-PLPs carrying OVA+CpG or nano-PLPs carrying 
OVA+CpG. 29 days after inoculation, lymphoid organs and serum was collected for 
immunological analysis and the remaining mice were sacrificed according to tumor 
progression. Similar to our previous observations, we found that while PLPs did promote 
greater activation of germinal center B cells (Figure 49) and improve antibody production 
overall. Further, we again observed Th1 associated class-switching to IgG2b and IgG2c 
only in mice that were treated with micro-PLPs, indicating that this immunological 












































Figure 50: PLP promote antibody secretion, but only micro-PLPs induce Th1-associated 




































































We then investigated how these differences in immunological response translated to 
therapeutic value by tracking tumor growth and survival in challenged mice. 
Interestingly, we observed that both PLP treatments prolonged survival by delaying 
tumor growth significantly compared to controls. However, mice eventually succumbed 
to their tumor burdens in both groups with very similar kinetics (Figure 51).  
 
Figure 51: (left) Tumors of mice treated with either PLP formulations grew at a similar 
rate. (right) Likewise, while tumors growth was delayed after PLP treatment, mice in 
both treatment groups eventually sustained lethal tumors.  
 
 
This finding has interesting implications for cancer immunotherapy design. While it is 
frequently hypothesized that a type 1 T cells response (and subsequent robust CTL 
activity) is necessary for efficient tumor elimination, here we show that there are perhaps 
multiple immunological mechanisms by which tumors may succumb to. Therefore, it 
may be most advantageous, in the end, to employ multiple therapeutic strategies 
simultaneously, to inundate the tumor’s defense systems and promote elimination.  
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T cell maturation and proliferation are hallmarks of an effective immune response and are 
critical for both killing of infected and cancerous cells as well as building a humoral 
response 186. It has been appreciated for decades now that dendritic cells play an essential 
role in initiation of an immune response by presenting antigens and stimulatory signals to 
dictate subsequent T cell responses 187. Recent literature has expanded on the breadth of 
DC mediated responses, including functional characterization of many subsets 188. These 
studies highlight the importance of studying how vaccine components interact with each 
of these subsets differently and what consequences this has for downstream immunity. 
Here we make an argument for the importance of the role of peripheral DC induction of T 
cell immunity. We have shown that not only are particles taken up by different peripheral 
DC subsets in a size dependent manner but their migration to draining lymph nodes and T 
cell engagement also varies with size. We have also observed that particle size can 
initiate different DC activation programs within the same subset, directly affecting T cell 
maturation.  
We suspect that the PDL2+ migratory DC subset may in fact include multiple 
subpopulations on its own and likely overlaps with other subsets that were screened in 
original trafficking assays. Therefore, the increase in PDL2+ DCs in the lymph node of 
mice treated with micro-PLPs may be indicative of a general preference for micro-sized 
carriers for many effector DCs in peripheral tissue. That in combination with the micro-
PLP’s ability to promote the production of a NFκB-mediated, pro-inflammatory DC 
cytokine profile could explain the Th1 skewing we observe. Additionally, micro-PLPs 
are able to induce a Th1 program, evident in T cell secretome and antibody class-
switching observations. This response is in line with expected results of a CpG 
oligonulceotide supplemented vaccine and our lab has previously shown the therapeutic 
value of micro-PLP delivered CpG in the context of a lymphoma vaccine 158.  
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Nano-PLPs, on the other hand, skew the immune response towards a Th2 biased 
response, as well as a more defined regulatory response. .  It has been shown previously 
that PLGA nanoparticles (400nm) can trigger the production of retinoic acid in dendritic 
cells isolated from cervical draining lymph nodes in vitro, leading to an increased 
induction of regulatory T cell proliferation 189. However, there are likely many other 
mechanisms by which this can happen, one of which we will describe in Aim 3.  
Interestingly, an increased occurrence of antigen-specific CD8+ T cells was also evident 
in nano-PMP treated mice. While this could be correlated with a number of events that 
are unknown to us in vivo, based on our data it’s possible that the increase migration of 
CpG-carrying plasmacytoid DCs may contribute to this increase in cytotoxic T cell 
proliferation. Traditionally, activated pDCs produce interferon-α, promoting a cytotoxic 
response. Interestingly, there is also evidence that peripheral pDCs that have become 
matured previously will subsequently become tolerogenic, inducing regulatory T cell 
proliferation 178. Further studies need to be performed to determine whether this is one 
cause of the increased regulatory response observed in mice treated with nano-PLPs. 
Overall, these observations provide evidence that vaccine carrier size can have a distinct 
effect on the immune response outcome and may play a synergistic or antagonistic role 
with molecular pattern induced signaling. This has significant implications in vaccine 
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CHAPTER 5  AIM 3  
INVESTIGATE MECHANISMS BEHIND SIZE-DEPENDENT DC 
PROGRAMMING 
Molecular signaling has been studied and established for many toll-like receptor (TLR) 
activation dependent pathways. As described previously, unmethylated CpG, found in 
bacterial and viral DNA sequences, is an agonist for TLR9. Signaling propagation is 
illustrated in Figure 5293. Signaling associated with activated TLR9 proceeds by 
recruitment of MyD88, followed by phosphorylation of the IRAK complex (including 
IRAK4). Following recruitment of TRAF6, signaling can split to promote either NFκB 
mediated transcription of inflammatory cytokines and costimulatory molecules or IRF7 


























Figure 52: Activated TLR9 can signal through MyD88 to promote either NFkB 
dependent transcription of inflammatory cytokines or IRF7 dependent type I IFN 





In this aim, we hypothesized that there are four points in the signaling propagation that 
could be influenced by particle parameters when delivering CpG (Figure 53). Due to the 
lack of IFNα/β produced by PLP-treated DCs (Aim 1), we decided to focus on NFκB-
mediated events. Specifically, we evaluated whether uptake kinetics varied between the 
two PLP formulations, TLR9-CpG ligation and signaling occurred rapidly after uptake, 
downstream NFκB-associated transcription events could be detected shortly thereafter 
and finally, whether we could detect major inhibitory signals that may block pro-










Figure 53: TLR9 signaling could be affected by the size of the CpG carrier at multiple 




Fluorescent CpG was custom made by Integrated DNA Technologies (Coralville, IA). 
Duolink Proximity Ligation Assay (PLA) kits and reagents were all purchased from 
Sigma (St. Louis, MO). Primary antibodies for PLA assays were purchased from 
Lifespan Biosciences (Seattle, WA). Raw-Blue NFκB reporter cells were purchased from 
Invivogen (San Diego, CA) and cultured according to manufacturer’s instructions. Anti-
phospho-STAT3 was purchased from BD Biosciences (Franklin Lakes, NJ). Antibodies 
against IRF4 and IRF8 were purchased from Ebioscience (San Diego, CA) and antibodies 
against IRF5 and IRF7 are from Life Technologies (Carlsbad, CA).   
5.1.2 Analysis of uptake preference by flow cytometry  
Uptake preference of isolated dendritic cell subsets was analyzed using flow cytometry. 
For flow cytometry experiments, PDL2+ or sorted pDCs were incubated with soluble or 
PEI-PLGA particle loaded APC-CpG for 24 hours. CpG dosage was kept constant at 
5ug/106 cells. Following incubation, cells were collected, washed, blocked for 
nonspecific Fc interactions using anti-mouse CD16/CD32 and stained with anti-mouse 
CD11c-PE-Cy7 and anti-mouse PDL2-PE antibodies according to previously published 
methods158. Cells were washed and resuspended in FACS buffer (PBS with 0.5% FBS) 
for analysis using a BD LSR II flow cytometer. Gates were applied to only include live, 
CD11c+ cells and both percent expression and mean fluorescent intensity were analyzed.    
5.1.3 TLR9-IRAK4 Proximity Ligation Assay 
BMDCs were sorted using a Pan DC Isolation kit (Miltenyi) to ensure purity. Cells were 
plated onto glass coverships and PLP formulations were added for 1 or 4 hours. Cells 
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were immediately fixed, blocked and stained with primary anti-TLR9 and anti-IRAK4  
overnight. The following day, cells were stained using the Duolink PLA system 
instructions. Coverslips were mounted onto glass slides using Prolong mounting medium 
and imaged using a spinning disc confocal microscopy. Quantification of punctae was 
performed using Volocity image analysis software.  
5.1.4 NFkB Activation Kinetics 
The RAW-Blue reporter cell line was used to determine NFkB activation kinetics. Cells 
were cultured according to manufacturer’s instructions and treated with particles for 1, 4, 
6, 24 or 48 hours. Supernatant was then collected and added to the QUANTI-BLUE 
detection medium per the manufacturer’s instructions.  
5.1.5 Phospho-STAT3 Kinetics  
Magnetic bead sorted (Pan DC Isolation Kit, Miltenyi) BMDCs were fixed, 
permeabilized and stained with anti-phopsho STAT3 (PY705). Cells were then analyzed 
using an Accuri C6 flow cytometer (BD).  
5.1.6 IRF 4/5/7/8 regulation  
Magnetic bead sorted BMDCs were fixed, permeabilized and stained with anti-IRF 
4/5/7/8 according to the manufacturer’s instructions. Cells were then analyzed using an 
Accuri C6 flow cytometer. Alternatively, cells were adhered to a glass slide before 
staining and analyzed using a Zeiss 700 Confocal microscope.  
5.1.7 Statistical Analysis 
Student’s t-test was used to perform statistical analysis between two groups, where 
p<0.05 was considered significant. In vitro experiments were conducted with n=6 to 
ensure reproducibility.  
 105 
5.2 RESULTS 
5.2.1 Micro- and nano-PLPs are taken up with similar kinetics 
While we have determined previously that various DC subsets exhibit preference towards 
a particular PLP formulation, we wanted to evaluate whether cells that did take up PLPs 
took up similar amounts of CpG and whether the kinetics of uptake were similar. This 
was done simply by quantifying fluorescence per cell (mean fluorescence intensity) of 
CpG+ cells in culture at multiple time points (1, 2, 4, 24 hours). We found that while 
soluble CpG was taken up more efficiently (faster and higher quantity), both PLP 
formulations were taken up at a similar rate. Additionally, cells that were CpG+ 
internalized equivalent amounts of CpG, regardless of carrier size (Figure 54). Therefore, 












































5.2.2 TLR9 signalig is delayed in nano-PLP treated BMDCs 
The next step in the signaling pathway is ligation of CpG and TLR9, resulting in 
activation of TLR9 and subsequent recruitment of MyD88 and other adaptor proteins, 
including IRAK4192,193. MyD88 must be sufficiently activated before adaptor proteins 
like IRAK4 are recruited; therefore, it is possible to indirectly test TLR9 activation by 
quantifying its proximity to IRAK4. We did this using the well-established proximity 
ligation assay194–196. Briefly, primary antibodies (anti-TLR9 and anti-IRAK4) are applied 
to cells, followed by secondary antibodies functionalized with DNA oligos that are then 
hydridized, ligated and amplified increase fluorescence. Hybridization is only possible 
when secondary antibodies are within 30-40nm, indicating that IRAK4 must be recruited 
to the TLR9 activation complex for a fluorescent signal to occur.  
We looked at TLR9 activation using this technique at early time points, specifically, 1 
and 6 hours post-PLP treatment. We observed that cells treated with micro-PLPs initiated 
TLR9 signaling as early as 1 hour after treatment and this signaling was no longer active 
6 hours after treatment. Inversely, signaling of TLR9 in cells treated with nano-PLPs was 
not evident until 6 hours post-treatment, indicating a significant delay in TLR9 activation 









 Figure 55: TLR9 activation is delayed in nano-PLP treated BMDCs but not in those 


























































5.2.2.1 NFκB-mediated transcription is delayed in nano-PLP treated BMDCs 
NFκB is the transcription factor that has been identified as the key promoter of pro-
inflammatory cytokine and co-stimulatory molecule production197–199. Because we have 
previously demonstrated a difference in cytokine production by cells given different PLP 
formulations (Aim 1), we wanted to investigate whether this was due to a difference 
NFκB activation kinetics. We quantified NFκB transcription using the Raw-Blue reporter 
cell line, which has a chromosomal incorporation of an NFκB-inducible secreted 
embryonic alkaline phosphatase (SEAP) reporter construct. We treated these cells with 
our PLP formulations (or soluble CpG) and quantified NFκB transcription over time. We 
observed that cells treated with both soluble or micro-PLPs have significant levels of 
NFκB-mediated transcription after 24 hours of treatment with PLPs. However, this was 
not observed for cells treated with nano-PLPs until 48 hours following treatment (Figure 
56). This delay is likely linked to the delay in TLR9 activation we observed previously 
and also explains the decreased production of pro-inflammatory cytokines (e.g. IL12p70) 










Figure 56: Activation of NFκB is delayed in cells treated with nano-PLPs.   
















5.2.3 Nano-PLPs induce rapid phosphorylation of STAT3 
STAT3 is implicated in negative regulatory processes in DCs, specifically initiation of 
pro-inflammatory signals200. Additionally, it is thought that the STAT3 transcription 
factor is responsible for controlling IL10 gene expression201,202. We, therefore, were 
interested in assaying whether the delay in NFκB activation or the IL10 secretion we 
observed in nano-PLP groups was caused by STAT3 activation. Our observations 
validated our hypothesis that STAT3 was phosphorylated rapidly and preferentially in 
cells treated with nano-PLPs. Specifically, STAT3 was activated within one hour in cells 
given nano-PLPs, while STAT3 in other groups was not activated to the same level until 
24 hours following treatment (Figure 57). In combination with the slower kinetics of 
NFκB activation, this is likely at least a partial explanation for the difference in 





































5.2.4 CpG-density play a critical role in modulating DC programming 
When working with biomaterial carriers, there are many parameters that may or may not 
prove important for immune modulation that are hard to decouple. For example, in order 
to provide consistent dosing of both CpG and PLGA in our experiments, we are required 
to allow the density of CpG on micro- vs. nano-PLPs remain variable. Specifically, the 
density of CpG loaded onto micro-PLPs is approximately four times the density on nano-
PLPs if they are loaded at the same w/w% (Table 5). Likewise, the amount of CpG 
loaded on the surface of PLPs directly affects their charge, thereby changing how they 
interact with cells132. Therefore, we evaluated how the size-dependent 
immunomodulation of PLPs on DCs is affected by ligand (i.e. CpG) density. We did this 
by loading the maximum amount of CpG onto nano-PLPs (Max nano-PLPs), providing 
us with a formulation with similar density to micro-PLPs. Using this system, we 
reassessed the kinetic profile of NFκB transcription and compared it with previously 
tested micro-PLP and nano-PLP formulations. We observed that when cells were treated 
with nano-PLPs that were density matched to micro-PLPs (Max-nano-PLPs) they no 
longer exhibited delayed NFκB transcription (Figure 58).  
 





 Zeta CpG Loading % Max Density Max Density 
mPLP -24.2±8.7 mV 13±1ug/mg 100%  1.83mg CpG/m2  
nPLP 4.65±4.12 mV 13±.0.1 ug/mg 26.8% 0.4mg CpG/m2 










Figure 58: Density matched PLPs (micro- and Max-nano) promoted the same NFκB 
transcription profiles.   
 
We went on to investigate whether STAT3 phosphorylation still occurred at the rapid rate 
observed with nano-PLP treated cells if they were instead treated with density matched 
nano-PLPs. Corroborating NFκB data, STAT3 phosphorylation was also decreased in 
cells treated with the Max-nano-PLP formulation compared to those treated with regular 
nano-PLPs. Interestingly, STAT3 phosphorylation in cells given Max-nano-PLPs never 
rose to the level that both nano-PLP and micro-PLP treated cells achieved, even at later 
time points (Figure 59). This indicates that there is still likely a size effect at play but we 





















































5.2.5 IRF4 may play a role in PLP mediated DC programming 
The interferon regulatory factor (IRF) family plays many roles in both the regulation of 
DC phenotypic development, as well as maturation203–206. In the context of TLR 
signaling, each IRF protein has a distinct role. IRF7 signaling diverges from the NFκB 
signaling pathway, promoting the production of Type 1 interferons (Figure 60, left)204. 
IRF5 and IRF8 both play roles in the NFκB pathway by complementing previously 
discussed adaptor proteins (Figure 60, middle)204. Lastly, IRF4 shares a binding domain 
on MyD88 with IRF5 and therefore serves as an regulatory factor by competitively 













Figure 60: IRF5/7/8 are mediators of various inflammatory responses while IRF4 






We therefore analyzed the kinetics of expression of each of these regulatory factors. First 
we analyzed the expression of IRF8 at 24 hours. We did not suspect that IRF8 would play 
a large regulatory role in these cells, since it has been established previously that BMDCs 
cultured with GMCSF+IL4 are regulated primarily via IRF4, not IRF875. Our hypothesis 

















We also suspected that IRF7 did not play a large role in the DC program we’ve observed 
due to the lack of Type 1 interferon present in our DC cultures. Our hypothesis proved to 
be correct, as we did not see an appreciable difference in IRF7 expression between cells 


































Given these findings, we hypothesized that the counterbalance between IRF4 and IRF5 
binding to MyD88 play a significant role in the eventual activation of downstream 
transcription factors and subsequent production of DC signals. We did find IRF5 
expression varies with treatment and that it is present in smaller amounts in cells treated 











Figure 63: IRF5 expression varies in response to different formulations and over time. 
Nano-PLPs (not density matched) have the lowest exprsesion of IRF5 over all time 
points. However, all three PLP formulations induce a decrease in IRF5 expression 


























IRF4 expression followed a very similar expression pattern, with the lowest expression 














Figure 64: IRF4 expression over time is influenced by formulation treatment. PLPs, 
especially nano-PLPs induce a significant reduction of IRF4 expression over all time 


























It is also known that activated IRF4 and IRF5 translocate from the cytoplasm, where it 
interacts with MyD88, to the nucleus, where it can act as a cofactor or regulator of 
transcription. We therefore utilized confocal microscopy to determine where IRF4 and 
IRF5 were located within the cells (Figure 65). According to these preliminary results, 
there is a significant amount of both IRF4 and IRF5 in the nuclei of cells regardless of 
treatment. However, IRF4 expression does seem to decrease over time in most groups, 
which corroborates our flow analysis. However, this data does not provide us grounds for 















Figure 65: Microscopic evaluation of IRF4 and IRF5 localization. (red: IRF5, 
















To gain greater insight into size-driven DC programming, we investigated multiple points 
in the TLR9 - NFκB axis, including PLP uptake, TLR9 signaling through MyD88 to 
IRAK4, transcription events of NFκB activation and NFκB inhibition through STAT3 
phosphorylation (Figure 53). While uptake did not vary significantly between the two 
carriers over time we did observe a kinetic variation in TLR9 signaling. TLR9 activation 
occurred within one hour in cells treated with micro-PLPs but was delayed in cells treated 
with nano-PLPs, remaining equivalent to untreated cells at 1 hour, but signaling strongly 
by 6 hours post-treatment .  
This led us to investigate whether the observed delay in signaling resulted in slower 
NFκB transcription, where we observed an equivalent delay in cells treated with nano-
PLPs. This informs the observations made earlier than nano-PLP treated cells not only 
expressed less CD86 but also produced significantly less IL12p70 after 24 hours of PLP 
treatment. It is known that CpG induces a regulatory response in parallel with pro-
inflammatory signals, hallmarked by production of IL10, to keep the immune response in 
check 207. STAT3 plays a major role in the transcription of the IL10 gene and also 
inhibits NFκB activity. Furthermore, STAT3 inhibition has been linked to regulatory T 
cell ablation 208. We therefore measured phosphorylation of STAT3 over time in PLP 
treated cells and observed that nano-PLP treatment did promote activation of STAT3. 
Taken together, the implication is that STAT3 dominates signaling in nano-PLP treated 
cells in early stages of DC programming, promoting a phenotype consistent with 
tolerogenic DCs and regulatory T cell phenotype development. IL10 in these cultures can 
also have an autocrine effect, promoting IL4 producing T cells 209.  
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Multiple modes of activation have been described for STAT3, one being through the 
IL10-receptor binding of extracellular IL10 210. However, based on the time scale of our 
observations, another mechanism must be dominant. We hypothesize that, in our system, 
STAT3 could be activated downstream of the PI3K pathway, which is independent of 
MyD88-IRAK4 activation and can be initiated very quickly after TLR activation 211,212. 
Furthermore, it has been shown that activation of PI3K and downstream STAT3 both 
result in the enhancement of IL10 production and decrease in pro-inflammatory cytokine 
(i.e. IL12p70) production, similar to our observations 213. Interestingly, it has also been 
demonstrated that type 1 interferons (e.g. IFNα) can induce activation of the IL10 
promoter via STAT3, potentially linking the plasmacytoid and regulatory responses we 
observed in our in vivo studies 214. 
Due to the greater surface to volume ratio of smaller spherical particles, ligand density is 
a variable that is linked to size. Specifically, at maximum loaded conditions, nano-PLPs 
were able to accommodate about 4 times more CpG than micro-PLPs. We discovered that 
the delay in NFκB transcription associated with nano-PLP treatment was completely 
recovered when the CpG density was matched to micro-PLPs. Interestingly, 
phosphorylation of STAT3 was also inhibited and remained ablated compared to micro or 
nano-PLP treated cells over the course of the experiment.  
It has been described for other TLRs (TLR1/2) that clustering is required for robust 
signaling215. It has been suggested that clustering may also promote hyperactivation for 
other TLRs, including TLR9216. Furthermore, it has been described recently by Ohto et 
al. that TLR9 forms a homodimer following ligation with a stimulatory CpG molecule, 
preceding signal propagation217. This could be one explanation for the density-dependent 
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graded response we have observed. It also begs the question of how signaling kinetics 
influences eventual programming. For example, it is known that there is a significant 
amount of crosstalk between different signaling axes, including those of NFκB and 
STAT3218–220. Therefore, it is possible that ligand-receptor avidity and rate of signaling 
may provide sufficient stimulation for one pathway but not the other, allowing the first to 
dominate programming. Another hypothesis involves the finding that CpG that forms 
high-order structures provides more efficient signaling motifs221. Therefore, it is possible 
that CpG delivered at a higher density is perceived by TLR9 as a higher ordered 
structure, promoting stronger signaling. Overall, this finding encourages further study 
into these interactions and could provide a means of fine-tuning immunity using CpG 
density. In general, the findings in this aim are incredibly promising and indicate that 
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CHAPTER 6  CONCLUSIONS AND FUTURE DIRECTIONS  
6.1 CONCLUDING SUMMARY 
Every year there are significant strides in medicine, yet there are diseases that plague 
huge portions of the population that remain unchecked. These range from infectious 
diseases (tuberculosis, malaria, HIV) to endogenous disease (cancer) to autoimmunity 
(diabetes, lupus, colitis). Dysregulation of the immune system is the link between all of 
these otherwise very different diseases. Immunotherapy provides an alternative to other 
medical approaches by teaching the body of the patient how to respond appropriately to 
its aberrant state. However, in order for an immunotherapeutic approach to be successful, 
it must be designed to simultaneously stimulate a robust response from the appropriate 
effector cells and overcome regulatory hurdles.  
Polymer-based particulate delivery vehicles have emerged as one of the most promising 
strategies for a wide range of immunotherapeutic applications. Particulate systems 
provide a modular platform for delivering a large variety of synthetic or biologic drugs. 
Furthermore, the ease at which physical parameters can be modulated offers as many 
permutations of particulate immunotherapeutic systems as there are applications.  
It has now been well established that there are many pathogen associated molecular 
patterns (PAMPs) that stimulate immune cells and promote robust, long-term responses. 
In addition to molecule signatures, pathogens come in a variety of shapes, sizes, charges 
and material compositions. However, there is still no conclusion whether these physical 
parameters contribute significantly to generation or alteration of the immune response. 
Likewise, this has also not been established for particle systems. In this work, we 
investigated whether a select couple of important physical parameters (i.e. size and ligand 
density) play a role in immunomodulation. We employed a pathogen-like microparticle 
(mPLP) system that our lab has extensively published on, in addition to a nano-scaled 
version of the same PLP system (nPLP).  
 123 
We first examined whether our particles exhibited any ability to passively target 
particular subsets of phagocytes present at the site of injection. By injecting PLPs loaded 
with fluorescently labeled CpG, we were able to determine both when and where the 
particles were in the lymph nodes and identify which dendritic cell subsets were 
responsible for transport of the PLPs. Using this strategy, we were able to pinpoint two 
subsets that made the most meaningful contributions to transport; these were PDL2+ 
dermal DCs and plasmacytoid DCs. Both cell types have been described previously in 
literature and are thought to promote a Th2 or a Th1 response, respectively. PDL2+ DCs 
have been detected in the dermis of mice and have been shown to efficiently migrate to 
mesenteric or skin-draining lymph nodes. Additionally, these cells are less sensitive to 
TLR agonists and can be derived from bone marrow cultures using GMCSF and IL4 
supplementation75. Plasmacytoid DCs, on the other hand, highly express TLRs that sense 
viral PAMPs and, upon activation, secrete large amounts of type 1 interferons, promoting 
cytotoxic T cell and type 1 helper responses. pDCs are found in both secondary lymphoid 
organs and in skin, especially during inflammation23,55. Therefore, by choosing these two 
subsets for PLP investigation allowed us to characterize PLP-DC interactions in two 
functionally distinct subsets.  
We immediately observed that DC subsets exhibited distinct preferences towards 
particular PLPs and that each PLP promoted unique DC programs. PDL2+ DCs 
preferentially took up micro-PLPs and they were also activated more efficiently by 
mPLPs, indicated by increased co-stimulatory expression and pro-inflammation shifted 
cytokine production. On the other hand, pDCs were more efficiently activated by nPLPs.  
One could rationalize that pDCs are more efficiently activated by nPLPs due to their 
resemblance to large virsus, but PDL2+ DC’s preference for mPLP was unexpected. 
Additionally, our finding that PDL2+ DC were capable of producing large amounts of 
pro-inflammatory cytokines following CpG stimulation countered previous literature, 
which indicated that PDL2+ BMDCs were not capable of this due to their spontaneously 
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matured nature. However, we argue that the previous characterization of PDL2+ as a 
marker identifying only Th2 programmed DCs is limited and PDL2+ may play a larger 
role in the activation state of DCs.  
PLP-treatment also correlated with distinct T cell functionality. We’ve described a 
distinct PLP-size dependent dichotomy present in T cell polarization. In vivo, we 
determined that this dichotomy persisted and was characterized by an mPLP driven Th1 
systemic response, hallmarked by high amounts of IgG2c, and an nPLP driven 
regulatory/ Th2 systemic response. These studies were performed at a constant antigen 
and adjuvant dose; therefore, size was the differentiating factor that drove these 
responses. One explanation for this lies in the mPLP preference of PDL2+ cells, which 
make up the majority of the migratory DCs in the skin draining lymph node. According 
to our in vitro studies, these cells also produce significant amounts of immunostimulatory 
cytokines, so likely are critical for robust immune response generation. Additionally, the 
increased regulatory response driven by nPLP treatment could play a role in skewing the 
T cell bias that may otherwise be more similar to that of mPLPs.  
IRF4 has also been shown to be an important regulator of DC differentiation and 
maturation203. It’s been implicated in many DC functions as well, including migration222. 
Based on our assessment of IRF4 expression after treatment with PLPs, it’s possible than 
nano-PLPs modulate IRF4 expression in a way that prohibits migration of some cells to 
the skin-draining lymph nodes, thereby influencing the immune response.   
To further characterize this response, we studied signaling along the well-characterized 
TLR9-NFκB axis to determine where it diverged between cells treated with mPLP or 
nPLP formulations. We’ve reported that TLR9 activation by nPLP delivered CpG is 
delayed significantly compared to mPLP delivery, resulting in subsequent inhibition of 
early NFκB controlled transcription. We have linked this inhibition to activation of 
STAT3, a known regulator of inflammation and promoter of IL10. Finally, for the first 
time, we have demonstrated that ligand density, a particle parameter that is inherently 
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linked to size, plays an essential role in signaling. By matching the density of CpG on the 
surface of mPLPs and nPLPs (Max-nPLP), we were able to shift DC programming from 
the original nPLP tropism.  
We hypothesize that this phenomenon could be a function of receptor clustering. TLR2 
has been shown to signal efficiency only after clustering215. Therefore, it’s possible that 
other receptors in the same family (i.e. TLR9) may respond in a similar way. While more 
studies would need to be done to test this hypothesis, it is a rational explanation for the 
ability of ligand density to induce such drastic changes in TLR9-initiated signaling.  
In conclusion, this work suggests that physical parameters of pathogens (e.g. size, ligand 
density, etc) play a influential role in the induction of signaling, whether by dictating 
receptor clustering or through another unknown mechanism. This can also be 
extrapolated to pathogen-like particle platforms, expanding the level of control we have 
over the immune response and significantly influencing immunotherapy design. 
Future work will include further characterization of the immunomodulatory potential of 
ligand density and investigation of the impacts of IRF4 downregulation as a result of PLP 
treatment. A gradient of ligand densities should be tested to determine the resolution of 
immunomodulation that can be achieved. Additionally, it should be tested with other 
TLR agonists to determine if the phenomenon is specific to TLR9’s interaction with 
CpG. In vitro migration studies can be conducted to validate whether IRF4 has an impact 
on DC mobility. Furthermore, in vivo migration studies using IRF4 knockout mice will 




6.2 FUTURE CONSIDERATIONS 
We feel that our observations are transformative to the immunoengineering and immunity 
research communities and provide critical steps to furthering our understanding of how 
innate immune cells interact with vaccine carriers and potentially also pathogens. 
However, as with most biological research, there were simplifying assumptions made. 
Therefore, it is important to consider the broad meaning of our observations in the 
context of real pathogenic infection and biological relevance.  
First, while we have broadly defined our two formulations as “virus like” (nano-PLPs) 
and “bacteria-like” (micro-PLP), it is know that the range of sizes associated with either 
pathogen is vast. For example, while the large majority of viruses are between 20 and 400 
nm in diameter, some viruses, like paramyxovirus, can be up to 14 microns long223. 
However, larger viruses like the paramyxovirus are filamentous and are not modeled 
properly by our carrier platform in any way. This leaves viruses that are icosahedral in 
shape, which are closely mimicked by our spherical particles. These viruses generally do 
not exceed 300nm and this structure describes a large percentage of the viral families 
significant for human diseases (Table 41-1)223. Bacteria are thought to be around one 
tenth the size of eukaryotic cells, ranging in size from 500nm to around 5 microns224,225. 
Again, our spherical platform does not sufficiently mimic the shape of rod-like (bacillus), 
spiral or any other unique shapes, but does provide a satisfactory model for the coccus 
family. This could provide us with valuable information, as cocci and bacilli make up the 
large majority of infectious bacterial families.  
In addition to the limiting factors of shape and size, it is also known that viral and 
bacterial pathogens carry many danger signals, including many of the pathogen 
associated molecular patterns (PAMPs) described in Chapter 2. Therefore, it is worth 
contemplating whether studying a single PAMP as an adjuvant is relevant when 
mimicking a pathogen. It is our opinion that infectious pathogens are incredibly complex 
and our understanding of how they trigger and simultaneously evade immune responses 
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is still not complete. Therefore, it is of the utmost importance that we use the 
investigation of simplified, individualized mechanisms in parallel with systems level 
characterization of pathogens themselves to teach the design of pathogen mimicking 
carriers. Furthermore, we believe that TLR9 agonist CpG is a particularly interesting 
molecule because it is found in both bacterial and viral DNA226,227. Interestingly, one 
investigator found that CpG motifs were relatively overrepresented in viruses with larger 
genomes (presumably making them physically larger) when compared to smaller viral 
genomes, perhaps indicating that our platform is even more qualified to represent larger 
viral pathogens228. Additionally, it has been shown that when CpG is deleted from viral 
vectors used for gene therapy, that the vectors become immune evasive, perhaps 
indicating that CpG provides one of the primary stimulatory signals associated many 
microbial pathogens229,230. We believe that all of this evidence motivates our studies, 
regardless of them being a simplified mimicry of natural pathogens. However, we also 
appreciate the utility of studying combinations of PAMPs to determine synergistic 
effects, and those studies are currently ongoing in our lab using the same particle 
platforms alongside mechanistic studies to investigate signaling associated with the 
synergy.  
The final point that has been raised by others confronted with this research relates to how 
our system mimics chronic infection, like that of bacterial or viral infection.  Because our 
particles degrade at a moderate speed (within 2-3 weeks of injection) they form a depot 
under the skin at the site of injection for that period of time. This gives resident innate 
immune cells sustained access to the particles carrying antigen and adjuvant, aptly 
imitating a site of injection where virus infected cells or bacteria would replicate over 
time. We argue that this provides a better model of injection than soluble injections, 
smaller particles or fast-degrading particles, as all of those are cleared from the site of 
injection quickly, limiting the modulatory potential of those platforms.    
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Overall, we feel that the conclusions drawn from the results in this work are not only 
important to the field of immunoengineering and vaccine design but also represent 






A.1. NANO-PLPs DECREASE INDUCED EXPRESSION OF PDL2 
Programmed death ligand 2 (PDL2) was originally discovered in the context of 
immunoregulation, as a ligand for programmed death receptor-1 (PD-1) on T cells231. It 
has been shown to promote T cell anergy and apoptosis and originally thought to play a 
role in tolerance. Furthermore, cancer cells express PDL2 (and PDL1) to induce 
activation-induced cell death of cytotoxic T cells and, therefore, immune evasion232. Only 
recently, PDL2 has been used as a characteristic marker for a new subset of DCs 
(PDL2+CD301b+ dermal DCs) that are skin-resident, migratory and play a significant 
role in Th2-driven immunity75,76. It was also established in this work that 
PDL2+CD301b+ DCs are phenotypically regulated by IRF4. 
 In our studies, PDL2+ dermal DCs appear in the draining lymph nodes within 24 hours 
of injection with fluorescent PLPs and they make up one of the largest populations of 
migratory CpG carrying DCs. We, therefore, chose this subset as one to study in vitro to 
characterize interactions between our PLPs and relevant migratory DC subsets. We 
confirmed that BMDC cultures supplemented with GMCSF and IL4 do indeed have a 
significant population of PDL2+ cells and that this populations remains intact after 
treatment with soluble CpG. We also observed that a large portion of these PDL2+ DCs 
were “induced” PDL2+ cells, that upregulated the expression of PDL2 after mechanical 
disruption (i.e. replating). These are different from the “spontaneously matured” 
population described by Gao et al., which express high levels of PDL2 in addition to 
other maturation markers (e.g. CD86, CD40)75. However, we observed that, in samples 
treated with micro- or nano-PLPs, the population expression of PDL2 was lower than in 
both untreated and soluble CpG treated cells. Since all samples were derived from the 
same original BMDC population, we made the assumption that the population of 
“spontaneously matured” cells. We therefore, deigned an experiment to verify this 
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assumption and determine the functional difference between spontaneously matured and 
induced PDL2+ DCs.  
A.1.1. MATERIALS AND METHODS 
A.1.1.1.  Materials 
Growth factors (GMCSF, IL4) were purchased from Peprotech (Rocky Hill, NJ). 
Antibodies against PDL2, CD11c, IL10 and TNFα were purchasesd from Ebioscience 
(San Diego, CA) and against IL12p70 was from BD Biosciences (Franklin Lakes, NJ).  
A.1.1.2. Quantification of spontaneously matured vs induced PDL2+ cells 
BMDCs were cultured for 6 days following the protocol described earlier. On Day 6, 
loosely adherent cells were isolated from original culture dishes and immediately stained 
with FITC-PDL2 to tag spontaneously matured cells. Cells were washed, replated at the 
appropriate density and treated with CpG formulations. After 24 hours, cells were 
collected and stained with PE-PDL2 to stain cells that expressed PDL2 between initial 
isolation and collection for analysis. Analysis was performed using an Accuri C6 flow 
cytometer. Double positive cells (FITC+PE+) were labeled spontaneously matured DCs 
and single positive (PE+) cells were labeled induced PDL2+ DCs.  
A.1.1.3. Intracellular staining for immunomodulatory cytokines 
Cells that were double stained for PDL2 were fixed and permeabilized using the protocol 
described previously. Cells were then stained for IL10, IL12p70 and TNFα to determine 
which subpopulation was responsible for cytokine production. Cells were analyzed using 




A.1.2.1. Quantification of spontaneously matured vs induced PDL2+ cells 
Figure 66 depicts the strategy used to differentiate spontaneously matured (PDL2.1) and 
induced (PDL2.2) PDL2+ DCs. Briefly, cells were stained with anti-PDL2-FITC 
immediately following isolation from original culture plates on Day 6. After washing, 
cells were replated and treated with CpG formulations. Following a 24 hour incubation 
period, cells were collected and stained with anti-PDL2-PE to differentiate cells that 
previously expressed PDL2 from those that gained expression following mechanical 







Figure 66: Schematic of spontanously matured (PDL2.1) and induced (PDL2.2) PDL2+ 




We found that cells that were untreated responded as previously described, where a large 
population of cells were induced by mechanical disruption to express PDL2. However, 
we observed that treatment with PLPs reduced this population, almost completely 











Figure 67: Induced PDL2 expression (PDL2.2+PDL2.1-) was almost completely 




A.1.2.2. Intracellular staining for immunomodulatory cytokines 
Earlier, we established that PDL2+ cells were responsible for production of the majority 
of immunomodualtory cytokines in these BMDC cultures. We were therefore interested 
in identifying whether spontaneously matured (PDL2.1) or induced (PDL2.2) cells 
contributed to this response. We found that spontaneously matured cells, despite previous 
observations made by Gao et al., were the primary producers of all three immunodulatory 







Figure 68: Spontaneously matured PDL2+ DCs (PDL2.1)  cells are responsible for 








































































































































































































The finding that mechanical disruption induced expression of PDL2 in nano-PLP treated 
samples is a novel finding with interesting implications. Other data we’ve collected up to 
this point also may result in an interesting regulatory mechanism. For example, we’ve 
already established that cells treated with nano-PLPs do not produce IFNγ, which is 
known to enhance the expression of PDL2233. Additionally, we have also shown that, 
while IRF4 expression is high in untreated cells in PDL2+ cultures (as described by Gao 
et al.) that nano-PLP treatment leads to significant downregulation of IRF4 protein 
content within the cells. This could lead to a variety of functional changes. Bajana et al. 
demonstrated that IRF4 positively regulates migration of skin-resident DCs222. Therefore, 
it is possible that the downregulation of IRF4 we observe in PDL2+ DCs cultured with 
nano-PLPs indicates that these cells also migrate less efficiently. This may explain the 
significant decrease in cells carrying nano-PLPs to the draining lymph node. We 
hypothesize that this is all linked to the expression of PDL2, however, more experiments 
need to be conducted to reach any definite conclusions. These include controlled in vitro 
and in vivo migratory studies as well as PDL2 knock down studies to pinpoint PDL2’s 
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